Banner
Poster Presentations Session III - Wednesday May 20, 2009

Click on the topic below to view posters
POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday May 20, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS: Wednesday May 20, 2009 - 8:00AM-3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday May 20, 2009 - 9:30AM-10:30AM
DISMANTLE: Wednesday May 20, 2009 - 3:00PM-3:30PM

CARDIOVASCULAR DISORDERS Clinical Outcomes Studies
PCV1 EVALUATING CLINICAL OUTCOMES OF AN EMPLOYER SPONSORED MULTI CENTER DIABETES AND HYPERTENSION MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) 
Pinto SL, Bechtol R, Kumar J
University of Toledo, Toledo, OH, USA 
   
PCV2  UNDERSTANDING PATIENTS DIAGNOSED WITH ATHEROSCLEROSIS AND THEIR DIAGNOSIS AND TREATMENT PATTERNS 
Jensen MM1, Costa-Scharplatz M2, Fox KM3, Gandhi SK4
1AstraZeneca R&D, Lund, Sweden, 2AstraZeneca R&D Sodertalje, Sodertalje, Sweden, 3University of Maryland School of Medicine, Monkton, MD, USA, 4AstraZeneca, LP, Wilmington, DE, USA 
   
PCV3  MEDIATING ROLE OF CEREBROVASCULAR DISEASE IN THE ASSOCIATION BETWEEN DIABETES MELLITUS AND DEMENTIA 
Lu Z, Stuart B, Zuckerman IH
University of Maryland School of Pharmacy, Baltimore, MD, USA 
   
PCV4  THE ASSOCIATION OF CO-MEDICATIONS AND CO-MORBIDITIES AND RISK OF DEMENTIA, IN PATIENTS WITH CHRONIC HEART FAILURE 
Agarwal SJ, Johnson ML
University of Houston, Houston, TX, USA 
   
PCV5  DEVELOPMENT OF TESTS FOR EARLY DIAGNOSIS OF PREECLAMPSIA 
Schiff L1, Foster T1, Creeden J2, van der Helm W2, Gartemann J2, Pashos CL1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Roche Diagnostics, Ltd, Rotkreuz, Switzerland 
   
PCV6  BURDEN OF HYPERLIPIDEMIA AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES 
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany 
   
PCV7  BURDEN OF HYPERTENSION AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES 
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany 
   
PCV8  COMPARING CARDIOVASCULAR EVENT RATES OF STATIN PLUS FIBRATE COMBINATION THERAPY WITH STATIN MONOTHERAPY IN SUBJECTS WITH TYPE-2 DIABETES MELLITUS 
Suh HS, Doctor JN
University of Southern California, Los Angeles, CA, USA 
   
PCV9  COMPARATIVE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH CHRONIC HEART FAILURE 
Chitnis A1, Sharma M1, Yadav R2, Chen H1, Aparasu R1, Johnson ML1
1University of Houston, Houston, TX, USA, 2College of Pharmacy, University of Houston, Houston, TX, USA 
   
PCV10  COMPARATIVE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH CHF 
Desai R1, Chen H1, Morgan R2, Johnson M1
1University of Houston, Houston, TX, USA, 2University of Texas, Houston, TX, USA 
   
PCV11  POINT-OF-CARE INR MONITORING DEVICES FOR PATIENTS ON LONG-TERM ORAL ANTICOAGULATION THERAPY 
Khan T
Ontario Ministry of Health and LongTerm Care, Toronto, ON, Canada 
   
PCV12  FONDAPARINUX IS ECONOMICALLY NON-INFERIOR TO ENOXAPARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM 
Bonafede MM1, Shorr AF2, Johnson BH1, Horblyuk R3
1Thomson Reuters, Cambridge, MA, USA, 2Washington Hospital Center, Washington, DC, USA, 3GlaxoSmithKline, Philadelphia, PA, USA 
   
PCV13  CAN THE RELATIONSHIP BETWEEN AGE AND CHOLESTEROL LEVELS INDICATE EFFECTIVENESS OF LIPID LOWERING THERAPY IN PRIMARY CARE? FRANCE, GERMANY, ITALY AND UK 
Blak BT1, Hards M1, Maguire A1, Schwalm MS2
1CSD EPIC, London, UK, 2Cededim Strategic Data, Paris, France 
   
PCV14  CLINnICAL AND ECONOMIC OUTCOMES IN PATIENTS SWITCHED TO SIMVASTATIN IN A COMMUNITY-BASED PRIMARY CARE SETTING 
Willey VJ1, Reinhold JA1, Willey KH2, Kelly BL2, Cziraky MJ3
1University of the Sciences, Philadelphia, PA, USA, 2Quality Family Physicians, Hockessin, DE, USA, 3HealthCore, Inc., Wilmington, DE, USA 
   
PCV15  EFFECT OF STATIN THERAPY ON RISK OF CORONARY DISEASE IN PRIMARY AND SECONDARY PREVENTION TRIALS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 
Liu JA, Shi L
Tulane University, New Orleans, LA, USA 
   
PCV16  RISK OF RE-BLOCKING AN ARTERY AFTER A TREATMENT AS A FACTOR OF EPISODE GROUPING 
Nowrouzi-Kashan F
Kentucky State University, Frankfort, KY, USA 
   
PCV17  ASSOCIATION BETWEEN PHARMACY TREATMENT AND OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE 
Shah DH1, Agarwal SJ2, Ashton CM3, Johnson ML2
1Abt Bio-Pharma Solutions, Inc., Waltham, MA, USA, 2University of Houston, Houston, TX, USA, 3Methodist Institute for Technology, Innovation, and Education, Houston, TX, USA 
   
PCV18  ADHERENCE TO STATIN TREATMENT AND ACHIEVING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) GOALS IN AN EMPLOYEE POPULATION 
Chen CY1, Burton WN2, Schultz AB1, Tunceli K3, Edington DW1
1University of Michigan, Ann Arbor, MI, USA, 2University of Illinois, Chicago, IL, USA, 3Merck & Co., Inc., Whitehouse Station, NJ, USA 
   
PCV19  EFFECT OF ACE INHIBITORS/ARBS AND STATINS ON THE INCIDENCE OF DEMENTIA, IN PATIENTS WITH CHRONIC HEART FAILURE 
Agarwal SJ, Johnson ML
University of Houston, Houston, TX, USA 
   
PCV20  ESTIMATE THE 10-YEAR CARDIOVASCULAR RISK IN THE GENERAL PUBLIC OF HONG KONG 
Lee VWY, Law SL, Lee KK
The Chinese University of Hong Kong, Shatin, Hong Kong 
   
PCV21  PREVALENCE, AWARENESS, AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNINSURED AND INSURED ADULTS IN THE UNITED STATES 
McDonald M1, Hertz RP1, Lustik MB2, Unger AN1
1Pfizer, New York, NY, USA, 2Science Applications International Corporation, Reston, VA, USA 
   
PCV22  VARIATION OF SEASONAL, WEEKLY AND DAILY RHYTHM OF ACUTE MYOCARDIAL INFARCTION IN DIABETIC PATIENTS 
Gabara K1, Boncz I1, Csoboth I1, Szovak E1, Varga A1, De Blasio A1, Bódi J1, Kriszbacher I2
1University of Pécs, Pécs, Hungary, 2University of Pécs, Pecs, Hungary 
   
PCV23  SEASONAL, WEEKLY AND DAILY VARIATION OF ACUTE MYOCARDIAL INFARCTION AND TRANSIENT ISCHEMIC ATTACK IN HUNGARY 
Kriszbacher I1, Boncz I2, Gazdag L2, Mátyus A2, Vránics I2, Csoboth I2, De Blasio A2, Zsigmond E2, Betlehem J1, Oláh A1, Bódis J1
1University of Pécs, Pecs, Hungary, 2University of Pécs, Pécs, Hungary 
   
PCV24  DAILY ALCOHOL CONSUMPTION AND RACE/ETHNICITY: THEIR RELATIONSHIP TO STROKE OR CORONARY ARTERY DISEASE IN THE US ADULT POPULATION 
Becker TL, Campbell HM
Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA 
   
PCV25  SMOKING AND STROKE IN THE CHINESE SMOKING POPULATION 
Wang L1, Li Y2
1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China 
   
PCV26  HEALTH CARE UTILIZATION AND RISK OF CARDIOVASCULAR DISEASE ASSOCIATED WITH METABOLIC SYNDROME 
Zang W1, Liu G2, Luo N3
1Southwestern University of Finance and Economics, Chengdu, Sichuan, China, 2Peking University, Beijing, Beijing, China, 3National University of Singapore, Singapore, Singapore 
   
PCV27  THE PREDICTION OF STROKE AND MORTALITY OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION MAINTAINING SINUS RHYTHM WITH AND WITHOUT ANTIARRHYTHMIC DRUGS 
Xenakis JG1, Quon P2, Getsios D3, White SA4, Khaykin Y5
1United BioSource Corporation, Lexington, MA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3United BioSource Corporation, Concord, MA, USA, 4Biosense Webster, Inc, Diamond Bar, CA, USA, 5Southlake Regional Health Centre, Newmarket, ON, Canada 
   
PCV28  THE CLINICAL IMPACT OF DIFFERENCES BETWEEN TWO MEASURES OF THE INTERNATIONAL NORMALIZED RATIO (INR) 
Shermock KM1, Pinto BL2, Streiff M2
1The Johns Hopkins Hospital, Baltimore, MD, USA, 2The Johns Hopkins Medical Institutions, Baltimore, MD, USA 
   
PCV29  RANDOMISED, FLEXIBLE DOSE STUDY TO COMPARE THE EFFICACY AND SAFETY OF NIFEDIPINE SUSTAINED RELEASE WITH GINGKGO BILOBA EXTRACT TO TREAT PATIENTS WITH PRIMARY RAYNAUD'S PHENOMENON; KOREAN RAYNAUD (KOARA) STUDY 
Choi WS1, Suh DC2, Lee JB3, Choi CJ4, Kim KS4, Chang M5, Kim CM1
1Catholic University, Seoul, South Korea, 2Rutgers University, Piscataway, NJ, USA, 3Korea University, Ansan, South Korea, 4Catholic University, Medical College, Seoul, South Korea, 5Bayer Schering Pharma, Bayer Korea Ltd, Seoul, South Korea 
   
PCV30  THE ASSOCIATION OF ASPIRIN USE ON RISK OF HOSPITALIZATION IN CHF PATIENTS TAKING ACE INHIBITORS: A RETROSPECTIVE ANALYSIS OF A NATIONAL COHORT OF VETERANS 
Parikh NM1, Shah DH2, Deswal A3, Ashton CM4, Agarwal SJ5, Chen H5, Johnson M5
1Analysis Group, Inc., Boston, MA, USA, 2Abt Bio-Pharma Solutions, Inc., Waltham, MA, USA, 3Baylor College of Medicine; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 4Methodist Institute for Technology, Innovation, and Education, Houston, TX, USA, 5University of Houston, Houston, TX, USA 
CARDIOVASCULAR DISORDERS Cost Studies
PCV31  US BUDGET IMPACT OF INCREASING ASPIRIN USAGE FOR PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE 
Benedict A1, Manson SC2, Pan F3, Wittrup-Jensen KU4, Fendrick AM5
1United BioSource Corporation, Budapest, Hungary, 2United BioSource Corporation, London, UK, 3United BioSource Corporation, Bethesda, MD, USA, 4Bayer Schering Pharma AG, Berlin, Germany, 5University of Michigan, Ann Arbor, MI, USA 
   
PCV32  HEALTH ECONOMICS EVALUATION ON PERCUTANEOUS CORONARY INTERVENTION(PCI) IN CHINA 
Han F1, Xiong X1, Tao L2, Xu P3, Liu S3
1China Health Insurance Research Association, Beijing, China, 2Johnson & Johnson Medical AP, Beijing, China, 3Johnson & Johnson Medical China, Beijing, China 
   
PCV33  A LIFE-LONG COST-EFFECTIVENESS MARKOV MODEL COMPARING HIGH-DOSE VERSUS STANDARD DOSE STATIN THERAPY IN ACUTE CORONARY SYNDROME PATIENTS 
Plesnila-Frank C1, Asukai Y2, Ehlken B1, Giannitsis E3, Rieber J4, Berger K1, Mardekian J5, Rublee DA5
1IMS Health, Munich, Germany, 2IMS Health, London, UK, 3University Hospital Heidelberg, Heidelberg, Germany, 4University of Munich, Munich, Germany, 5Pfizer, New York, NY, USA 
   
PCV34  FINANCIAL ASSESSMENT OF A COMPREHENSIVE CARDIAC CARE PROGRAM FOR PATIENTS WITH OCCULSIVE CORONARY ARTERY DISEASE 
Delate T1, Olson K1, Rasmussen J2, Hutka K2, Sandhoff B2, Hornak R2, Merenich J2
1Kaiser Permanente Colorado, Aurora, CO, USA, 2Kaiser Permanente Colorado, aurora, CO, USA 
   
PCV35  PHARMACOECONOMIC MODEL OF ENOXAPARIN VERSUS HEPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN MEDICAL PATIENTS 
Milani-Jr R1, Follador W2, Gonçalves J2, Di Sena V2
1São Paulo University, São Paulo, São Paulo, Brazil, 2Sanofi-Aventis, São Paulo, São Paulo, Brazil 
   
PCV36  THE IMPACT OF A STATIN FORMULARY CHANGE ON HEALTH OUTCOMES AND MEDICAL COSTS 
Vlahiotis A1, Cox E2
1Express Scripts, Inc., Saint Louis, MO, USA, 2Express Scripts, Inc., Maryland Heights, MO, USA 
   
PCV37  ECONOMIC IMPACT OF EDARAVONE THERAPY FOR PATIENTS WITH LACUNAR INFARCTION IN JAPAN 
Inoue S1, Okuda S2, Yamaguchi T3
1Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 2National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan, 3National Cardiovascular Center, Suita, Osaka, Japan 
   
PCV38  COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PROPHYLAXIS AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT IN KOREA 
Kim J1, Pollock R2, Jung S3, Diamantopoulos A4, Lees M5
1IMS Health, Seoul, South Korea, 2IMS Health, Basel, Switzerland, 3Bayer Korea, Seoul, South Korea, 4IMS Health, London, UK, 5Bayer HealthCare, Uxbridge, UK 
   
PCV39  COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP AND KNEE REPLACEMENT IN PORTUGAL 
Mateus C1, Wolowacz S2, Pereira JA3
1Universidade Nova de Lisboa, Lisbon, Portugal, 2RTI Health Solutions, Manchester, UK, 3Universidade Nova de Lisboa, Lisboa, Portugal 
   
PCV40  COST-EFFECTIVENESS ANALYSIS OF THE INSERTABLE CARDIAC MONITOR FOR DETECTING RECURRENT ATRIAL FIBRILLATION (AF) FOLLOWING RADIOFREQUENCY CATHETER ABLATION (RCA): A CANADIAN PERSPECTIVE 
Sadri H1, Tsintzos S2, Yee R3, Skanes A3, Gula L4
1Medtronic of Canada Ltd, Toronto, ON, Canada, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, 3London Health Sciences Centre, London, ON, Canada, 4University of Western Ontario, London, ON, Canada 
   
PCV41  ADHERENCE TO GUIDELINES FOR SENSITIVITY ANALYSIS: COST-EFFECTIVENESS ANALYSES OF DUAL ORAL ANTIPLATELET THERAPY 
Mauskopf J1, Schmitt C2, Boye KS3, McCollam PL3, Juniper M1, Birt JA3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK, 3Eli Lilly and Company, Indianapolis, IN, USA 
   
PCV42  INCREMENTAL COST-EFFECTIVENESS ANALYSIS OF ANGIOTENSIN RECEPTOR BLOCKERS IN HYPERTENSIVE PATIENTS IN A US MANAGED CARE POPULATION 
Miller LA1, Wade R2, Cziraky MJ3, Dai D3, Mayo K4, Ramsawany K4
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2HealthCore, Inc., Wilmington, DC, USA, 3HealthCore, Inc., Wilmington, DE, USA, 4Daiichi Sankyo, Inc., Parsippany, NJ, USA 
   
PCV43  WHICH PUBLIC POLICY IS MORE COST-EFFECTIVE IN REDUCING CARDIAC DEATHS: INCREASED TAXES OR SMOKING BANS? 
Menke JM1, Malone DC2
1University of Arizona, Tucson, AZ, USA, 2University of Arizona College of Pharmacy, Tucson, AZ, USA 
   
PCV44  WITHDRAWN
   
PCV45  ECONOMIC ANALYSIS OF THE INSERTABLE CARDIAC MONITOR IN DIAGNOSIS OF SYNCOPE COMPARED TO CONVENTIONAL DIAGNOSTICS: A CANADIAN PERSPECTIVE 
Sadri H1, Tsintzos S2, Winsor P3, Yee R4
1Medtronic of Canada Ltd, Toronto, ON, Canada, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, 3Medtronic of Canada, Mississauga, ON, Canada, 4London Health Sciences Centre, London, ON, Canada 
   
PCV46  COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING FLUVASTATIN XL 80 MG INTO THE BRAZILIAN NATIONAL DRUG FORMULARY 
Godoy MR1, Bueno RLP2, Suzuki C3
1UFRGS - Federal University of Rio Grande do Sul, São Paulo, São Paulo - SP, Brazil, 2FEI, São Paulo, Brazil, 3Novartis Biociências S/A, São Paulo, Brazil 
   
PCV47  COST-EFFECTIVENESS OF ADD-ON EARLY STRESS MYOCARDIAL PERFUSION IMAGING FOR ASIAN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN BUT NON-DIAGNOSTIC ELECTROCARDIOGRAPHY -- THE ACUTE CHEST PAIN TREATMENT & EVALUATION STUDY (ACTION) 
Ow MY1, Lim SH2, Chua TS3, Wee HL1
1National University of Singapore, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore, 3National Heart Centre Singapore, Singapore, Singapore 
   
PCV48  USING EXPERT ELICITATION TO INFORM ADOPTION AND RESEARCH DECISIONS FOR ENHANCED EXTERNAL COUNTERPULSATION IN ANGINA 
McKenna C, Claxton K, Hawkins NS, Sculpher M
University of York, York, UK 
   
PCV49  ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN FOR THE NON-INVASIVE MANAGEMENT OF PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES (NSTE-ACS): THE PHARMACOECONOMIC EVALUATION IN RUSSIA 
Syrov A1, Zyryanov S2, Belousov YB2
1Moscow hospital of GUVD, Moscow, Russia, 2Russian State Medical University, Moscow, Russia 
   
PCV50  COST CONSEQUENCES ANALYSIS OF ANTITHROMBOTIC THERAPIES FOR VENOUS THROMBOEMBOLIC DISEASE (VTE) IN MEDICAL PATIENTS IN MEXICO 
Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2, Dorantes-Aguilar J1, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico 
   
PCV51  A COST-EFFECTIVENESS ASSESSMENT OF DALTEPARIN AS A PROPHYLACTIC AND THERAPEUTIC AGENT FOR THE MANAGEMENT OF THROMBOEMBOLIC VENOUS DISEASE (VTE) IN MEXICAN ADULT PATIENTS AFTER TOTAL HIP REPLACEMENT 
Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2, Dorantes-Aguilar J1, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico 
   
PCV52  ECONOMIC EVALUATION OF DALTEPARIN FOR THE MANAGEMENT OF THROMBOEMBOLIC VENOUS DISEASE (VTE) AFTER TOTAL KNEE ARTHROPLASTY IN MEXICO 
Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2, Dorantes-Aguilar J1, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico 
   
PCV53  A PHARMACOECONOMIC ANALYSIS OF PROPHYLAXIS THERAPIES AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN MEXICAN PATIENTS WITH CANCER 
Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2, Dorantes-Aguilar J1, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico 
   
PCV54  COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS AGED OVER 75 YEARS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY 
Wolowacz S1, Roskell N1, Plumb J2, Clemens A2, Robinson P3, Dolan G4, Brenkel I5
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3Boehringer Ingelheim Ltd, Bracknell, UK, 4Nottingham University Hospitals, Nottingham, UK, 5Fife Acute Hospitals NHS Trust, Dunfermline, UK 
   
PCV55  COST-EFFECTIVENESS OF VALSARTAN IN JAPAN: RESULTS FROM THE JIKEI HEART STUDY 
Shimizu M1, Crawford B2, Ikewaki K1, Taniguchi I1, Kamae I3, Dahlof B4, Drost P5, Mochizuki S1
1Jikei University School of Medicine, Tokyo, Tokyo, Japan, 2Mapi Values, Tokyo, Meguro, Japan, 3Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 4Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden, 5Mapi Values, AX Houten, AX Houten, Netherlands 
   
PCV56  COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION 
Wolowacz S1, Roskell N1, Plumb J2, Clemens A2, Robinson P3, Dolan G4, Brenkel I5
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3Boehringer Ingelheim Ltd, Bracknell, UK, 4Nottingham University Hospitals, Nottingham, UK, 5Fife Acute Hospitals NHS Trust, Dunfermline, UK 
   
PCV57  HEALTH ECONOMIC EVALUATION OF CONTRAST MEDIA IN CORONAROGRAPHY: ISO-OSMOLAR IODIXANOL VS. LOW-OSMOLAR MEDIA 
Vorobiev P1, Lesnicheva M2, Tyrsin OY3
1Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, 2Russian Society For Pharmacoeconomics and Outcomes Research, Moscow, Russia, 3Nycomed Russia-CIS, Moscow, Russia 
   
PCV58  TRIAL-BASED ECONOMIC EVALUATION ALONGSIDE THE TCYB (TAKE CONTROL OF YOUR BLOOD PRESSURE) TRIAL 
Reed SD1, Li Y1, Oddone EZ2, Neary AM2, Orr MM2, Grubber JM2, Graham FL1, Olsen MK2, Svetkey LP3, Dolor RJ2, Powers BJ3, Adams MB3, Bosworth HB2
1Duke Clinical Research Institute, Durham, NC, USA, 2Durham Veterans Affairs Medical Center, Durham, NC, USA, 3Duke University Medical Center, Durham, NC, USA 
   
PCV59  ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL 
Eisenstein EL1, Edwards R1, Cowper PA1, Kong DF1, Silverstein MD2, Mark DB1, Anstrom KJ1, Wijns W3
1Duke Clinical Research Institute, Durham, NC, USA, 2Health Care Research, Bellaire, TX, USA, 3Cardiovascular Center, Aalst, Belgium
   
PCV60  ECONOMIC ANALYSIS OF ENDEAVOR VS. CYPHER STENTS: RESULTS FROM THE ENDEAVOR III TRIAL 
Eisenstein EL1, Leon MB2, Kandzari DE3, Edwards R1, Cowper PA1, Kong DF1, Silverstein MD4, Mark DB1, Anstrom KJ1
1Duke Clinical Research Institute, Durham, NC, USA, 2Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA, 3Scripps Clinic, La Jolla, CA, USA, 4Health Care Research, Bellaire, TX, USA 
   
PCV61  MEDICAL EXPENDITURES ATTRIBUTABLE TO CORONARY ARTERY DISEASE IN THE UNITED STATES 
Slejko JF, Sullivan PW
University of Colorado Denver, Aurora, CO, USA 
   
PCV62  IDENTIFYING DRIVERS OF POST-HOSPITAL DISCHARGE FOR PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) USING QUANTILE REGRESSIONS 
Zhao Z, Yurgin N, Winget M
Eli Lilly and Company, Indianapolis, IN, USA 
   
PCV63  INPATIENT BURDEN OF ILLNESS AND PREDICTORS OF CHARGES OR LENGTHS OF STAY AMONG ADULT HEART TRANSPLANTATION PATIENTS 
Olvey EL, Skrepnek GH
University of Arizona, Tucson, AZ, USA 
   
PCV64  ECONOMIC BURDEN OF ATHEROSCLEROSIS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS 
Ohsfeldt RL1, Gandhi SK2, Fox KM3, Bullano M2
1Texas A & M Health Science Center, College Station, TX, USA, 2AstraZeneca, LP, Wilmington, DE, USA, 3University of Maryland School of Medicine, Monkton, MD, USA 
   
PCV65  MANAGEMENT OF PRIMARY ATRIAL FIBRILLATION (AF): PATIENT CHARACTERISTICS AND HOSPITAL CARE SETTING 
Spalding JR1, Exuzides A2, Colby C2, Neil N2, Noe L2
1Astellas Pharma US, Inc., Deerfield, IL, USA, 2ICON Clinical Research, San Francisco, CA, USA 
   
PCV66  INPATIENT RESOURCE USE AMONG PATIENTS TREATED FOR PRIMARY ATRIAL FIBRILLATION (AF): ROLE OF CLINICAL FACTORS AND CHOICE OF INITIAL CONVERSION THERAPY 
Spalding J1, Exuzides A2, Colby C2, Neil N2, Noe L2
1Astellas Pharma US, Inc., Deerfield, IL, USA, 2ICON Clinical Research, San Francisco, CA, USA 
   
PCV67  COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL INFARCTION: STUDY ON 12049 INDIVIDUALS USING ADMINISTRATIVE DATABASES 
Mantovani LG1, Fornari C2, Madotto F2, Riva M2, Chiodini V2, Ferrario M3, Merlino L4, Zocchetti C4, Cesana G2
1University Federico II, Naples, Italy, 2University of Milano-Bicocca, Monza, Lombardia, Italy, 3University of Insubria, Varese, Lombardia, Italy, 4Lombardy Region, Milano, Italy 
   
PCV68  ADMINISTRATIVE CLAIMS IN A LARGE BRAZILIAN NATIONWIDE DATABASE: A DESCRIPTIVE ANALYSIS OF THE DIRECT MEDICAL COSTS OF CORONARY ARTERY BYPASS GRAFTING (CABG) AMONG DIFFERENT REGIONS IN A CONTINENTAL-SIZE COUNTRY 
Fonseca MCM1, Abicalaffe CL2, Muranaka AH3, Araujo GT1
1UNIFESP -- Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Impacto Tecnologias Gerenciais em Saude, Curitiba, Parana, Brazil, 3Universidade Federal de São Paulo, Sao Paulo, SP, Brazil 
   
PCV69  A CONCEPTUAL ANALYSIS OF THE COSTS OF CARE FOR A “MAJOR BLEED” IN STUDIES OF ANTIPLATELET AND ANTITHROMBOTIC THERAPIES 
Harshaw Q1, Frye C1, Hauch O2
1EPI-Q, Inc., Oak Brook, IL, USA, 2AstraZeneca, LP, Wilmington, DE, USA 
   
PCV70  WITHDRAWN
   
PCV71  COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS SIMVASTATIN: WILL THE INCREASED RISK OF CANCER MAKE EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE? 
Wang CC, Biddle AK, Farley JF
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 
   
PCV72  COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR PERSPECTIVE 
Kutscherauer P1, Kodym R2, Bartaskova D3
1Novartis Pharmaceuticals Corporation, Prague, Czech Republic, 2Novartis Pharmaceuticals Corporation, Prague 3, Czech Republic, 3Charles University, Prague, Czech Republic 
   
PCV73  INCREASED PATIENT THROUGHPUT AND REDUCTION IN LABORATORY STAFF AND LABOR INTENSITY WITH THE USE OF REGADENOSON 
Smalarz AM1, Denevich S2, Boulanger L1, Spaulding J3
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Abt Associates, Inc., Lexington, MA, USA, 3Astellas Pharma US, Inc., Deerfield, IL, USA 
   
PCV74  PREDICTED REDUCTION IN HOSPITAL DAYS AND ASSOCIATED COSTS AMONG MANAGED CARE PRIMARY AND SECONDARY RISK MIXED DYSLIPIDEMIA PATIENTS TREATED WITH FIXED DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN COMBINATION THERAPY 
Simko RJ1, Balu S1, Webb SF1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA 
CARDIOVASCULAR DISORDERS Patient-Reported Outcomes Studies
PCV75  IMPACT OF MEDICATION ADHERENCE ON CARDIOVASCULAR DISEASE-RELATED HEALTH CARE COST AMONG PATIENTS TREATED WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG DYSLIPIDEMIA PATIENTS IN A MANAGED CARE POPULATION 
Balu S1, Simko RJ1, Webb SF1, Yu J2, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA 
   
PCV76  RELATIONSHIP BETWEEN HEALTH LITERACY, OUTCOME EXPECTATIONS, EFFICACY EXPECTATIONS AND MEDICATION ADHERENCE 
Bhor M1, Plake KS2, Chen JT2
1Abbott Laboratories, Abbott Park, IL, USA, 2Purdue University, West Lafayette, IN, USA 
   
PCV77  EVALUATION OF AN EDUCATIONAL ANTIHYPERTENSIVE MEDICATION ADHERENCE TOOL: IMPACT ON ANTIHYPERTENSIVE ADHERENCE AND BLOOD PRESSURE CONTROL 
Bui CN1, Hanson KA2, Prasla K1, Godley PJ1, Frech-Tamas F2, Rascati KL3
1Scott and White Health System, Temple, TX, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3University of Texas at Austin, Austin, TX, USA 
   
PCV78  INTERVENTIONS TO IMPROVE MEDICATION COMPLIANCE IN HYPERTENSION: QUALITATIVE AND QUANTITATIVE SYSTEMATIC REVIEW 
Lal LS1, Manias E2, Salas M3, Gwadry-Sridhar F4
1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2University of Melbourne, Carlton, Australia, 3AstraZeneca, LP, Wilmington, DE, USA, 4University of Western Ontario, London, ON, Canada 
   
PCV79  WITHDRAWN
   
PCV80  MEDICATION ADHERENCE AND CARDIOVASCULAR DISEASE-RELATED HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS TREATED WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION 
Balu S1, Simko RJ1, Webb SF1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA 
   
PCV81  MEASURING THE IMPACT OF SOCIO-DEMOGRAPHIC CHARACTERISTICS ON PATIENT PERSISTENCE IN CHRONIC MARKETS 
Henderson SC1, Denarie MF2, Yuan Y1
1IMS Health, Blue Bell, PA, USA, 2IMS Health, Plymouth Meeting, PA, USA 
   
PCV82  FRACTION OF NURSING HOME ADMISSION AND INCREMENTAL COST ATTRIBUTABLE TO NON ADHERENCE TO ANTI HYPERTENSIVE MEDICATIONS 
Rapp T, Schneider M, Zuckerman IH
University of Maryland, Baltimore, MD, USA 
   
PCV83  WITHDRAWN
   
PCV84  WITHDRAWN
   
PCV85  WITHDRAWN 
   
PCV86  FLUSHING ASSESSMENT TOOL (FAST): PSYCHOMETRIC PROPERTIES OF A NEW MEASURE ASSESSING FLUSHING SYMPTOMS 
Kawata AK1, Thakkar R2, Davidson MH3, Punzi HA4, Jiang P2, Li D2, Krause S2, Padley R2, Revicki DA1
1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3University of Chicago, Chicago, IL, USA, 4Punzi Medical Center and Trinity Hypertension Research Institute, Carrollton, TX, USA 
   
PCV87  IS MEASURING HEALTH STATUS BENEFICIAL IN HEART FAILURE PATIENTS? 
Höfer S1, Frick M1, Pölzl G1, Benzer W2
1Medical University Innsbruck, Innsbruck, Austria, 2Academic Hospital Feldkirch, Feldkirch, Austria 
   
PCV88  EVALUATION OF COMPARATIVE EFFECTIVENESS: A MODEL FOR GENERATING HYPOTHESES AND DETERMINING SAMPLE SIZE 
Bharmal M1, Cascade EF2, Gemmen EK1
1Quintiles, Inc, Falls Church, VA, USA, 2iGuard, Inc, Falls Church, VA, USA 
CARDIOVASCULAR DISORDERS Health Care Use & Policy Studies
PCV89  DIABETES MANAGEMENT AND KNOWLEDGE IMPROVEMENTS AS A RESULT OF PATIENT EDUCATION: A COMMUNITY BASED, RANDOMIZED CLINICAL TRIAL 
Winston RA1, Lu Z2, Shaya FT2, Laird A1, Saunders E3
1Bon Secours Baltimore Health System, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA 
   
PCV90  PHARMACEUTICAL SPENDING ON CHRONIC DISEASES IN CONSUMER DIRECTED HEALTH PLANS 
Kadiyala S1, Mullainathan S2, Spackman DE1
1University of Washington, Seattle, WA, USA, 2Harvard University, Cambridge, MA, USA 
   
PCV91  DISPARITIES IN CORONARY ARTERY DISEASE CARE AMONG ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE 
Hawkins K1, Escoto KH2, Ozminkowski RJ3, Bhattarai GR4, Marshall JK5, Harbin HT6, Migliori RM7
1Ingenix, Brooklyn, MI, USA, 2Ingenix, Eden Prairie, MN, USA, 3UnitedHealth Group Alliances, Ann Arbor, MI, USA, 4Ingenix, Rocky Hill, CT, USA, 5Ingenix, MINNEAPOLIS, MN, USA, 6AARP, Washington, DC, USA, 7UnitedHealth Group Alliances, MINNETONKA, MN, USA 
   
PCV92  HOW DOES THE OUT-OF-POCKET PAYMENT MATTER TO HYPERTENSIVE PATIENTS' CHOICES OF ACCESSING DIFFERENT MEDICAL FACILITIES IN TAIWAN? THE PRELIMINARY STUDY OF A DISCRETE CHOICE EXPERIMENT 
Lee YY, Chen LC, Lee CJ, Lee CS
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 
   
PCV93  CARDIOVASCULAR RISK (ACCORDING TO FRAGMINHAN) FOLLOW-UP OF A COHORT INSCRIBED IN THE DE TODO CORAZON (DTC) DISEASE MANAGEMENT PROGRAMME OF MUTUAL SER HMO IN COLOMBIA, 2004-2007 
Paz J1, Pardo R2, Morales C1, Rodriguez N2, Granados CE2, Buitrago L2, Guete AM3, Caceres HA4
1Asociación Mutual Ser ESS EPS-S, Cartagena, NA, Colombia, 2Universidad Nacional de Colombia, Bogotá, NA, Colombia, 3Pfizer, Cartagena, NA, Colombia, 4Pfizer, Bogotá D.C, Colombia 
   
PCV94  ASSESSMENT OF THE STATUS OF HYPERTENSION MANAGEMENT IN NEWLY DIAGNOSED AND ESTABLISHED HYPERTENSION PATIENTS IN PRIMARY CARE PRACTICE 
Kim J1, Phatak HM2, Biskupiak J3, Wu D2
1University of Utah, Salt Lake City, UT, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA, 3University of Utahof Pharmacy, Salt Lake City, UT, USA 
   
PCV95  ELECTRONIC MEDICAL RECORD USE AND WARFARIN DRUG-DRUG INTERACTIONS DURING AMBULATORY VISITS IN THE UNITED STATES, 2003-2006 
Meek PD, Renaud-Mutart AC, Cosler LE
Albany College of Pharmacy and Health Sciences, Albany, NY, USA 
   
PCV96  ASSOCIATIONS BETWEEN BASELINE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS AND TREATMENT INITIATION OF SELECTED STATINS IN A MANAGED CARE POPULATION 
Tunceli K1, Sajjan S2, Ramey DR3
1Merck & Co., Inc., Whitehouse Station, NJ, USA, 2Merck & Co., Inc., West Point, PA, USA, 3Merck & Co., Inc., Upper Gwynedd, PA, USA 
   
PCV97  TEN-YEARS FOLLOW-UP OF ANTI-HYPERTENSIVE MEDICATIONS WITHIN THE SLOVAK REPUBLIC 
Tesar T, Foltan V, Binder R
Comenius University, Bratislava, Slovak Republic 
   
PCV98  ADHERENCE TO MAINTENANCE MEDICATIONS BY DAYS SUPPLY AND DISTRIBUTION CHANNEL 
Liberman JN1, Wang Y1, Hutchins DS2
1CVS Caremark Corporation, Hunt Valley, MD, USA, 2CVS Caremark Corporation, Scottsdale, AZ, USA 
   
PCV99  A LONGITUDINAL ANALYSIS OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) PRESCRIBING PATTERNS UNDER A PRIOR-AUTHORIZATION REQUIREMENT 
Kahan NR, Waitman DA, Vardy DA
Leumit Health Fund, Tel-Aviv, Israel 
   
PCV100  PATTERN OF CLOPIDOGREL USE IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS 
Yu HT1, Dean BB1, Bae JP2, Fiske S1, Xiong Y1, Emons MF1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA 
   
PCV101  A REVIEW OF TREATMENT PATTERNS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN THREE EUROPEAN COUNTRIES 
Angalakuditi M1, Wright D2, Gaskin M3, Farkhoury W3
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Health, London, UK, 3IMS Health, London, London, UK 
   
PCV102  INFLUENCE OF COPAYMENT DIFFERENTIAL BETWEEN GENERIC AND PREFERRED BRAND PRESCRIPTIONS DRUGS ON GENERIC FILL RATE 
Yuan Y1, Carlson AM2, Gleason PP3, Schommer JC4
1IMS Health, Blue Bell, PA, USA, 2Data Intelligence Consultants LLC, Eden Prairie, MN, USA, 3Prime Therapeutics LLC, Eagan, MN, USA, 4University of Minnesota, Minneapolis, MN, USA 
   
PCV103  ASSOCIATION BETWEEN COPAYMENT AND ADHERENCE TO STATIN TREATMENT IN A VETERAN POPULATION: A RETROSPECTIVE ANALYSIS 
Bounthavong M1, Kazerooni R1, Christopher MLD1, Mendes M1, Juzba M2, Plowman BK1, Morreale AP1
1Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA, 2Department of Veterans Affairs (Long Beach), Long Beach, CA, USA 
   
PCV104  ANALYSIS OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS IN THE US MEDICAID PROGRAM FROM 1991 TO 2007 
Bian B1, Li X2, Jing Y3, Guo JJ2, Kelton CM2, Wigle PR2
1University of Cincinnati, Cincinnanti, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA 
   
PCV106  CREATING A QUALITY INDEX TO RANK HOSPITALS 
Baser O
University of Michigan and STATinMED Research, Ann Arbor, MI, USA 
   
PCV107  SPECIFICITY OF ADMINISTRATIVE DATA FOR IDENTIFYING HEART FAILURE PATIENTS FOR HOSPITAL QUALITY PERFORMANCE INITIATIVES 
Bautista A1, Stein BD2, Lee TA3, Meltzer DO2, DiDomenico R1, Krishnan JA2, Schumock GT1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Chicago, Chicago, IL, USA, 3Hines VA Hospital and Northwestern University, Chicago, IL, USA 
   
PCV108  USE OF RENIN SYSTEM AGENTS AMONG HYPERTENSION PATIENTS WITH RENAL DISEASE IN A MANAED CARE SETTING 
Stern L1, Lamerato L2, Ogbonnaya A1, Hwa Ong S3, Munk VC3, Charney A4
1Analytica International, New York, NY, USA, 2Henry Ford, Detroit, MI, USA, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 
   
PCV109  THERAPY INTERRUPTIONS IN PATIENTS SWITCHED FROM BRANDED TO OTHER GENERIC STATINS 
Chapman RH1, Benner JS1, Girase P2, Benigno M3, Axelsen KJ3, Liu L3, Nichol MB4
1IMS Health, Falls Church, VA, USA, 2IMS Health, Watertown, MA, USA, 3Pfizer Pharmaceuticals, New York, NY, USA, 4University of Southern California, Los Angeles, CA, USA 
   
PCV110  DO CANADIAN PHYSICIANS CORRECTLY IDENTIFY HIGH RISK CV PATIENTS? 
Beamer B, Liovas A
AstraZeneca, Mississauga, ON, Canada 

POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday May 20, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS: Wednesday May 20, 2009 - 8:00AM-3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday May 20, 2009 - 9:30AM-10:30AM
DISMANTLE: Wednesday May 20, 2009 - 3:00PM-3:30PM

INDIVIDUAL’S HEALTH Clinical Outcomes Studies
PIH1  ASSESSMENT OF LENGTH OF STAY FOR WOMEN WITH HIGH RISK COMORBIDITIES DURING LABOR AND DELIVERY 
Patel AM, Syeda SS, Wu WK
St. John's University, Queens, NY, USA 
   
PIH2  CLINICAL AND COST OUTCOMES AMONG PATIENTS ON WARFARIN WITH ELECTRONIC ALERTS TO REMIND PROVIDERS ABOUT HIGH INTERNATIONAL NORMALIZED RATIO 
Selvan MS, Peymann P, Flowers P, Murphy R, Shabot M
Memorial Hermann Healthcare System, Houston, TX, USA 
   
PIH3  SYSTEMATIC LITERATURE REVIEW OF THE GYNECARE PROLIFT® PELVIC FLOOR REPAIR SYSTEM TREATMENT OUTCOMES 
Sikirica V1, Robinson D1, Kirkemo A1, Hinoul P2, Meek J1, Jones SH1, Perkins HE1
1Ethicon, Inc a Johnson & Johnson Company, Somerville, NJ, USA, 2Ethicon, Inc a Johnson & Johnson Company, CEDEX, France 
   
PIH4  PERSONALIZED MEDICINE: TRENDS IN CLINICAL STUDIES BASED ON NATIONAL REGISTRY DATA 
Nellesen D, Person A, Yee K, Chawla A
Analysis Group, Inc., Menlo Park, CA, USA 
   
PIH5  AN ANALYSIS OF SELECT INJURY-INCREASING ANALGESIC MEDICATIONS IN MEDICARE DUAL ELIGIBLE ENROLLEES 
Blackwell SA, Montgomery MA, Baugh DK, Ciborowski G, Levy JM
Centers for Medicare & Medicaid Services, Baltimore, MD, USA 
   
PIH6  DEVELOPING EVIDENCE-BASED TRADITIONAL CHINESE MEDICINE THROUGH OUTCOME RESEARCH 
Lai JN1, Wang JD2
1National Yang-Ming University, Taipei, Taiwan, 2National Taiwan University, College of Public Health, Taipei, Taiwan 
INDIVIDUAL’S HEALTH Cost Studies
PIH7  COMPARISON OF LEVONORGESTREL INTRAUTERINE SYSTEM (LNG-IUS) TO TUBAL LIGATION FOR CONTRACEPTION: A COST-EFFECTIVENESS ANALYSIS 
Niyazov A1, Gricar JA2
1Long Island University, Brooklyn, NY, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH8  COMPARISON OF LEVONORGESTREL INTRAUTERINE SYSTEM (LNG-IUS) TO ORAL CONTRACEPTIVES (OC) ON CONTRACEPTION: A COST-EFFECTIVENESS ANALYSIS 
Niyazov A1, Gricar JA2
1Long Island University, Brooklyn, NY, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH9  A SIMULATION MODELING OF THE EFFECT OF DOSING SCHEDULE ON THE BENEFIT AND COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN CANADA 
Ismaila AS1, Pereira JA1, Robson RC1, Rawson NS1, Simpson SD1, Standaert BA2
1GlaxoSmithKline, Mississauga, ON, Canada, 2GlaxoSmithKline Biologicals, Rixensart, Belgium 
   
PIH10  COST EFFECTIVENESS OF ORAL BISPHOSPHONATES ADMINISTERED ON EXTENDED DOSING INTERVALS 
Moore E1, Devine JW1, Trice S1, Mistry HH1, Potyk R1, Nwokeji ED2
1Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA, 2University of Texas at Austin, Austin, TX, USA 
   
PIH11  ECONOMIC EVALUATION ALONGSIDE THE CAFFEINE FOR APNEA OF PREMATURITY (CAP) TRIAL: SHORT TERM OUTCOMES 
Dukhovny D1, Lorch SA2, Schmidt B2, Doyle LW3, Kok JH4, Roberts RS5, Kamholz K6, Wang N1, Zupancic JA1
1Harvard Medical School, Boston, MA, USA, 2University of Pennsylvania School of Medicine, Philadelphia, PA, USA, 3University of Melbourne, Melbourne, Victoria, Australia, 4Emma Children's Hospital Academic Medical Center, Amsterdam, Netherlands, 5McMaster University, Hamilton, ON, Canada, 6Boston University School of Medicine, Boston, MA, USA 
   
PIH12  COMPARISON OF YAZ TO SSRIS IN THE TREATMENT OF PREMENSTRUAL DYSPHRORIC DISORDER: COST-EFFECTIVENESS ANALYSIS 
Rendas-Baum R1, Yang M1, Gricar JA2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH13  COST-EFFECTIVENESS OF A SCHOOL-BASED TOBACCO-USE PREVENTION PROGRAM IN SPAIN 
Ramos Goñi J1, Linertova R2, Ramallo Fariña Y1, Torres Lana A3
1FUNCIS, S/C Tenerife, Canarias, Spain, 2Servicio de Evaluación y Planificación, Santa Cruz de Tenerife, Spain, 3Health Service, S/C Tenerife, Canarias, Spain 
   
PIH14  COST-EFFECTIVENESS OF NEONATAL SCREENING FOR CONGENITAL ERRORS OF METABOLISM USING TANDEM MASS SPECTROMETRY 
Ramos Goñi J1, Serrano Aguilar P2, Sáenz-Torres M3, Posada M4
1FUNCIS, S/C Tenerife, Canarias, Spain, 2Canary Island Health Care Services, S/C Tenerife, Canarias, Spain, 3Health Department of Basque Country, Bilbao, Basque Country, Spain, 4Instituto Carlos III, Madrid, Madrid, Spain 
   
PIH15  COST EFFECTIVENESS ANALYSIS OF GOSERELIN EMPIRIC THERAPY FOR DEEP ENDOMETRIOSIS TREATMENT 
Araujo D1, Passos RBF2, Souza CPR2, Silva AP3, Marques M3
1State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2MedInsight, Rio de Janeiro, Brazil, 3AstraZeneca, São Paulo, Brazil 
   
PIH16  COST-EFFECTIVENESS ASSESSMENT OF LEVONORGESTREL INTRAUTERINE SYSTEM IN PATIENTS WITH IDIOPATHIC MENORRHAGIA IN A HONG KONG PUBLIC HOSPITAL 
Lee KK1, Lee VWY1, Tam WH2
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong, China 
   
PIH17  COST/EFFECTIVENESS STUDY OF CLOMIPHENE CITRATE VERSUS ANASTROZOLE IN THE INDUCTION OF OVULATION IN BARREN ADULT PATIENTS AT A MEXICAN PUBLIC HOSPITAL 
Martínez-Núñez JM1, Altagracia-Martínez M2, Kravzov-Jinich J2, Ríos-Castañeda LC3, Guadarrama-Atrizco MD2, Hinojosa-Cruz JC4
1Universidad Autónoma Metropolitana - Xochimilco, México, Mexico DF, Mexico, 2Universidad Autónoma Metropolitana - Xochimilco, Mexico, Mexico DF, Mexico, 3Instituto Nacional de Neurología y Neurocirugía, Mexico, Mexico DF, Mexico, 4Hospital de Gineco -- Obstetricia No. 3 Centro Médico Nacional “La Raza” IMSS, Mexico, Mexico DF, Mexico 
   
PIH18  A COST EFFECTIVENESS ANALYSIS OF A GENERAL VACCINATION PROGRAMME WITH THE NEW 10- VALENT PNEUMOCOCCAL NON- TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN- D CONJUGATE VACCINE (PHID-CV) IN SWEDEN 
Bergman A1, Borg S1, Sobocki P2, Persson U1
1The Swedish Institute for Health Economics, Lund, Sweden, 2GlaxoSmithKline AB, Solna, Sweden 
   
PIH19  EXPANDED NEWBORN SCREENING IN TEXAS: A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODELING 
Tiwana SK, Rascati KL
University of Texas at Austin, Austin, TX, USA 
   
PIH20  INCREMENTAL COST OF OTITIS MEDIA AMONG CHILDREN IN THE UNITED STATES 
Bharmal M1, Kamble S2
1Quintiles, Inc, Falls Church, VA, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA 
   
PIH21  DRIVERS OF HEALTH CARE COSTS IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) 
Foley K1, Foley D2, Shah H3
1Thomson Reuters, Philadelphia, PA, USA, 2Boehringer Ingelheim Ltd, Ridgefield, CT, USA, 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA 
   
PIH22  ESTIMATING DIRECT COST OF VAGINITIS IN TURKEY 
Tulunay FC1, Malhan S2
1Ankara University Medical School, Ankara, Turkey, 2Baskent University, Ankara, Turkey 
   
PIH23  A SYSTEMATIC REVIEW OF THE COST OF FALLS IN OLDER ADULTS: AN INTERNATIONAL PERSPECTIVE 
Davis JC1, Robertson MC2, Ashe MC1, Khan KM1, Marra CA1
1University of British Columbia, Vancouver, BC, Canada, 2University of Otago, Dunedin, New Zealand 
   
PIH24  AN INVESTIGATION OF THE EFFECTS OF GENDER, RACE, AGE, AND OTHER DESCRIPTIVE VARIABLES ON THE LENGTH OF HOSPITALIZATION AND TOTAL HOSPITALIZATION CHARGES ACCRUED BY PEDIATRIC INPATIENTS AFFLICTED WITH PHARYNGITIS 
Perry JD
University of Louisville, Louisville, KY, USA 
   
PIH25  DIRECT COST OF INFERTILITY TREATMENT IN TURKEY 
Malhan S1, Tulunay FC2
1Baskent University, Ankara, Turkey, 2Ankara University, Ankara, Turkey 
   
PIH26  THE ECONOMIC IMPACT OF SINGLETON, TWIN AND MULTIPLE GESTATION PREGNANCIES IN ALBERTA 
Chuck A, Yan C
Institute of Health Economics, Edmonton, AB, Canada 
INDIVIDUAL’S HEALTH Patient-Reported Outcomes Studies
PIH27  THE IMPACT ON ADHERENCE AND FORMULARY PERFORMANCE METRICS OF ALLOWING MEMBERS TO CHOOSE EITHER MAIL OR RETAIL PHARMACY FOR RECEIVING 90-DAY SUPPLY MAINTENANCE MEDICATIONS 
Hutchins DS1, Liberman JN2, Bradly A3
1CVS Caremark Corporation, Scottsdale, AZ, USA, 2CVS Caremark Corporation, Hunt Valley, MD, USA, 3CVS Caremark Corporation, Woonsocket, RI, USA 
   
PIH28  THE IMPACT OF MEDICARE SUPPLEMENT INSURANCE ON ACCESS, UTILIZATION, AND COST OF HEALTH CARE AND ON COMPLIANCE WITH RECOMMENDED PHARMACEUTICAL TREATMENT 
Marshall JK1, Ozminkowski RJ2, Anderson M3, Hawkins K4
1Ingenix, MINNEAPOLIS, MN, USA, 2UnitedHealth Group Alliances, Ann Arbor, MI, USA, 3UnitedHealth Group Alliances, MINNETONKA, MN, USA, 4Ingenix, Brooklyn, MI, USA 
   
PIH29  COMPARISON OF ADHERENCE, PERSISTENCE AND MEDICATION WASTAGE IN 30-DAY VERSUS 90-DAY REFILL CHANNELS 
Vats V1, Ziang J2, Lee KY3, Schumock GT1, Khandelwal NG3
1University of Illinois at Chicago, Chicago, IL, USA, 2Walgreens Health Initiatives, Deerfield, IL, USA, 3Walgreens Health Services, Deerfield, IL, USA 
   
PIH30  PATTERNS OF UTILIZATION AND DISCONTINUATION OF MEDICATION IN A RETIREE POPULATION 
Visaria J
Ohio State University, Columbus, OH, USA 
   
PIH31  ASSESSING THE VALUE OF LESS FREQUENT MEDICATION DOSING ON ADHERENCE AND OUTCOMES 
Veenstra DL1, Alfonso R1, Best JH2, Bruhn D3, Garrison LP1
1University of Washington, Seattle, WA, USA, 2Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA 
   
PIH32  THE BRAZILIAN PORTUGUESE VALIDATION OF THE PROLAPSE -- QUALITY OF LIFE QUESTIONNAIRE - P-QOL 
Scarlato A1, Fonseca ESM2, Fonseca MCM2, Muranaka AH3, Sartori MGF2, Girão MJBC2, Castro RA2
1Federal University of São Paulo, São Paulo, Brazil, 2UNIFESP -- Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 3Universidade Federal de São Paulo, Sao Paulo, SP, Brazil 
   
PIH33  LONGITUDINAL VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS) 
Yarlas AS1, Yang M1, Hammond GC1, Gricar JA2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH34  WITHDRAWN 
 
 
   
PIH35  DEVELOPMENT OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE (IPAQ) TO EVALUATE A NEW DEVICE TO ADMINISTER HUMAN GROWTH HORMONE (HGH) 
Etschmaier M1, Kimel M2, McCormack J2, Hey-Hadavi J1, Cara JF1
1Pfizer, New York, NY, USA, 2United BioSource Corporation, Bethesda, MD, USA 
   
PIH36  DEVELOPMENT OF A SPECIFIC QUESTIONNAIRE ASSESSING THE IMPACT ON PARENTS OF AN INFANT'S BRONCHIOLITIS HOSPITALIZATION 
Lapillonne A1, Gournay V2, Gouyon JB3, Moriette G4, Benmedjahed K5, Roborel de Climens A6, Arnould B6, Bendjenana H7
1Saint Vincent de Paul Hospital, Paris, France, 2University Hospital (CHU) of Nantes, Nantes Cedex, France, 3University Hospital (CHU) of Dijon, Dijon, France, 4Port-Royal Hospital, Paris, France, 5Mapi Values France, Lyon, France, 6Mapi Values, Lyon, France, 7Abbott Laboratories, Rungis Cedex, France 
   
PIH37  URINARY URGENCY INTENSITY RATING IN RELATION TO SYMPTOM FREQUENCY, BOTHER, AND TREATMENT SEEKING: RESULTS FROM EPILUTS IN THE US, UK, AND SWEDEN (SE) 
Thompson CL1, Coyne KS1, Sexton C1, Kopp Z2
1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer, New York, NY, USA 
   
PIH38  STATISTICAL ANALYSES OF FACTORS AFFECTING LENGTH OG STAY AND TOTAL CHARGES FOR PEDIATRIC PATIENTS AFFLICTED WITH PERINATAL INFECTION 
Tran DL
University of Louisville, Louisville, KY, USA 
   
PIH39  ASSOCIATION BETWEEN SEXUAL DRIVE CHANGE AND PREMENSTRUAL SYMPTOMS 
Yang M1, Hammond GC1, Yarlas AS1, Gricar JA2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH40  ASSESSING WORK PRODUCTIVITY IMPAIRMENT IN PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHRORIC DISORDER 
Hammond GC1, Yarlas AS1, Yang M1, Gricar JA2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Independent Health Care Consultant, New York, NY, USA 
   
PIH41  PATIENT SATISFACTION AND PERCEIVED CARE IN OBSTETRICIANS AND GYNECOLOGISTS COMPARED TO OTHER SPECIALTIES: ANALYSIS OF US SELF-REPORTED SURVEY DATA 
Patel I1, Chang J1, Feldman SR2, Balkrishnan R3
1University of Michigan at Ann Arbor, Ann Arbor, MI, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA, 3Ohio State University, Columbus, OH, USA 
   
PIH42  WORK DISABILITY AND RETIREMENT IN DUAL-EARNER FAMILIES 
Ilchuk S
The Pardee RAND Graduate School, Los Angeles, CA, USA 
   
PIH43  HOURLY AND ANNUAL OBJECTIVE PRODUCTIVITY (PRESENTEEISM) ACROSS SEVERAL DISEASES: BIPOLAR DISORDER, OTHER MENTAL DISORDERS, CHRONIC CONSTIPATION, FUNCTIONAL DYSPEPSIA, GERD, GOUT, AND INSOMNIA 
Brook RA1, Kleinman NL2, Melkonian AK3, Smeeding J4
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 3The HCMS Group, Cheyenne, WY, USA, 4The JeSTARx Group, Dallas, TX, USA 
   
PIH44  WORK PRODUCTIVITY OF WOMEN EXPERIENCING DOMESTIC VIOLENCE 
Cerulli C1, Lavigne J2, Richards H1, Caine E1
1University of Rochester, Rochester, NY, USA, 2St. John Fisher College, Rochester, NY, USA 
INDIVIDUAL’S HEALTH Health Care Use & Policy Studies
PIH45  THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT PREVIOUS DRUG COVERAGE 
LIU/Mr XQ, Walton SM, Crawford SY, Pickard AS
University of Illinois at Chicago, Chicago, IL, USA 
   
PIH46  OUTCOMES AND COSTS ASSOCIATED WITH FERTILITY DRUG THERAPY IN AN INSURED POPULATION WITH A STATE FERTILITY MANDATE 
Bowen KL
Excellus BlueCross BlueShield, Rochester, NY, USA 
   
PIH47  POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY USING JAPANESE BEERS CRITERIA 
Akazawa M1, Imai H2, Igarashi A3
1University of Tokyo, Bunkyo-ku, Tokyo, Japan, 2National Institute of Public Health, Wako, Saitama, Japan, 3University of Tokyo, Bunkyo, Tokyo, Japan 
   
PIH48  RELATIONSHIP BETWEEN DRUG COST COVERAGE AND PRESCRIPTION DECISION MAKING IN MEDICARE PART D ENROLLEES 
Hales JW1, Dudley S2, Hegamin A1, Poulios N3, Mills K1
1TUI University, Cypress, CA, USA, 2Meharry Medical College, Nashville, TN, USA, 3City University of New York, New York, NY, USA 
   
PIH49  HORMONE REPLACEMENT THERAPY: AN ANALYSIS FOCUSING ON DRUG CLAIMS BY FEMALE SENIORS 2000 TO 2007 
Gaucher M, Hunt J
Canadian Institute for Health Information, Ottawa, ON, Canada 
   
PIH50  USE OF CATEGORY X AND D API'S DURING PREGNANCY: A COMPARATIVE, RETROSPECTIVE, CROSS-SECTIONAL STUDY USING NAMCS AND NHAMCS DATABASES 
Mattoo PD, Pal S
St. John's University, Jamaica, NY, USA 
   
PIH51  RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG USE AMONG OLDER ADULTS IN THE UNITED STATES 
Qato D, Lindau ST, Conti R, Alexander GC
University of Chicago, Chicago, IL, USA 
   
PIH52  TARGETED COMMUNITY OUTREACH REDUCES OUT-OF-POCKET PRESCRIPTION DRUG COSTS OF MEDICARE PART D BENEFICIARIES 
Stebbins MR1, Patel RA2, Cutler TW1, Smith AR1, Shimomura S3, Patel V4, Tsunoda SM5, Mallari J6, Mirzaian E7, Lipton HL1
1University of California, San Francisco, San Francisco, CA, USA, 2University of the Pacific, Stockton, CA, USA, 3Western University of Health Sciences, Pomona, CA, USA, 4Touro University - California, Vallejo, CA, USA, 5University of California, San Diego, La Jolla, CA, USA, 6Loma Linda University, Loma Linda, CA, USA, 7University of Southern California, Los Angeles, CA, USA 
   
PIH53  IS MEDICARE PART D PLAN BENEFIT DESIGN ASSOCIATED WITH COST-RELATED NONADHERENCE TO PRESCRIPTION DRUGS? AN ANALYSIS USING THE MEDICARE CAHPS DATA 
Wei II, Howell BL, Frankenfield DL, Anderson KK, Sekscenski E
Centers for Medicare & Medicaid Services, Baltimore, MD, USA 
   
PIH54  HEALTH CARE UTILIZATION AND COSTS AMONGST WOMEN WITH FEMALE SEXUAL DYSFUNCTION (FSD) AND HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) 
Foley K1, Foley D2, Shah H3
1Thomson Reuters, Philadelphia, PA, USA, 2Boehringer Ingelheim Ltd, Ridgefield, CT, USA, 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA 
   
PIH55  WITHDRAWN
 
 
   
PIH56  CARESS: THE CANADIAN REGISTRY OF SYNAGIS® SUMMARY OF 2006-2008 RSV SEASONS 
Paes B1, Reim EK2, Lanctôt KL2, Mitchell I3
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3University of Calgary, Calgary, AB, Canada 
POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday May 20, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS: Wednesday May 20, 2009 - 8:00AM-3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday May 20, 2009 - 9:30AM-10:30AM
DISMANTLE: Wednesday May 20, 2009 - 3:00PM-3:30PM

MENTAL HEALTH Clinical Outcomes Studies
PMH1  ALPRAZOLAM-RELATED DEATHS IN WEST VIRGINIA 
Shah N, Smith MJ, Abate MA
West Virginia University, Morgantown, WV, USA 
   
PMH2  USE OF HYPNOTICS/ANXIOLYTICS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ASSOCIATIONS WITH CHRONIC PAIN, SLEEP DISORDERS, AND ANTIDEPRESSANT SELECTION 
Liu X1, Ye W2, Wohlreich M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA 
   
PMH3  DEPRESSION: ETHNIC DIFFERENCES IN PREVALENCE, DIAGNOSIS, AND SYMPTOMS 
Kannan H, Bolge SC, Wagner S
Consumer Health Sciences International, Princeton, NJ, USA 
   
PMH4  PREVALENCE OF DEPRESSION IN EUROPE: A COMPARISON OF FIVE COUNTRIES 
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany 
   
PMH5  PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT: A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA 
Wisniewski SR1, Whitehead R2, Ali M3, Jin N3, Kim E4, Nyilas M5, Carson WH5, Iwamoto T5, Mathew S2, Pikalov A2, Jing Y4
1University of Pittsburgh, Pittsburgh, PA, USA, 2Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 3Otsuka Pharmaceutical Development and Commercialization, Inc, Rockville, MD, USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA, 5Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA 
   
PMH6  A COMPARATIVE REVIEW OF SAFETY, EFFICACY AND ECONOMICS OF OFF-LABEL PRESCRIBING OF LEADING ATYPICAL ANTIPSYCHOTICS 
Mittal AR
St. John's University, Jamaica, NY, USA 
   
PMH7  PATIENT ASSESSED QUALITY OF LIFE VS. CLINICIAN ASSESSMENT IN A TRIAL OF ARIPIPRAZOLE IN PEDIATRIC PATIENTS WITH BIPOLAR DISORDER 
Whitehead R1, Chen CF2, Kim E3, Carson WH2, Iwamoto T2, Mathew S1, Pikalov A1, Jing Y3
1Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 2Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA 
   
PMH8  WITHDRAWN
   
PMH9  ADULT ADHD IN THE UNITED STATES: A COMPARISON OF 2 METHODS TO ESTIMATE PREVALENCE 
Montejano LB1, Sasane R2, Hodgkins P2, Huse D3
1Thomson Reuters, Washington, DC, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3Thomson Reuters, Cambridge, MA, USA 
   
PMH10  RISK OF INJURY IN ADULTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER 
Montejano LB1, Sasane R2, Hodgkins P2, Huse D3
1Thomson Reuters, Washington, DC, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3Thomson Reuters, Cambridge, MA, USA 
   
PMH11  RISK ASSESSMENT OF POISONING WITH DRUGS OF THERAPEUTIC IMPORTANCE BY TOXICOVIGILANCE 
Sam KG, Tunga G, Pandey S
Manipal University, Manipal, Karnataka, India 
   
PMH12  A META-ANALYSIS OF EFFICACY AND SAFETY OF PREGABALIN AND CLONAZEPAM IN THE TREATMENT OF ANXIETY DISORDERS 
Villasis-Keever MA1, Rivas-Ruiz R1, Mould-Quevedo J2
1Social Security Mexican Institute, Mexico City, Mexico, 2Pfizer Mexico, Mexico City, Mexico 
   
PMH13  WITHDRAWN
MENTAL HEALTH Cost Studies
PMH14  BUDGETARY IMPACT OF WELL DIRECTED USE OF PALIPERIDONE ER IN GERMANY 
Sindern J1, Mehnert A2, Schroeder-Bernhardi D3
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen-Cilag GmbH, Neuss, NRW, Germany, 3IMS Health GmbH & Co. OHG, Frankfurt/Main, Hessen, Germany 
   
PMH15  COSTS OF DEMENTIA IN HUNGARY 
Érsek K1, Karpati K1, Brodszky V1, Pentek M2, Boncz I3, Kovács T4, Gulacsi L1
1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3University of Pécs, Pécs, Hungary, 4Semmelweis University, Budapest, Hungary 
   
PMH16  COST-BENEFIT ANALYSIS OF FOUR ANTIPSYCHOTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIA IN COLOMBIA 
Rosselli D1, DeAntonio R2, Córdoba R1
1Independiente, Bogotá, DC, Colombia, 2Independent, Bogota, Colombia 
   
PMH17  HEALTH CARE COSTS ASSOCIATED WITH TREATMENT OF BIPOLAR DISORDER USING A MOOD STABILIZER PLUS ADJUNCTIVE ARIPIPRAZOLE, QUETIAPINE, RISPERIDONE, OLANZAPINE OR ZIPRASIDONE 
Jing Y1, Kim E1, Pikalov A2, Tran QV2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH18  HEALTH CARE RESOURCE UTILIZATION ANALYSIS OF PRE/POST LONG-ACTING RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS IN THREE REGIONAL PUBLIC HOSPITALS IN HONG KONG 
Lee KK1, Lee EH2, Lee VWY1, Chung DW2
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong, China 
   
PMH19  ECONOMIC ASSESSMENT OF SECOND-LINE TREATMENT: SWITCHING FROM A GENERIC SSRI TO ESCITALOPRAM, AN SNRI, OR ANOTHER GENERIC SSRI BY PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) 
Marynchenko M1, Yu AP2, Lauzon V1, Ramakrishnan K2, Wu EQ2, Ben-Hamadi R2, Erder MH3, Bose A3
1Analysis Group, Inc., Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Forest Research Institute, Jersey City, NJ, USA 
   
PMH20  RETROSPECTIVE COHORT STUDY OF THE EFFECTS OF EARLY VERSUS LATE TREATMENT OF INSOMNIA IN PATIENTS INITIATING ANTI-DEPRESSANT MEDICATIONS 
Delea T1, Hagiwara M1, Mallya U2
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 
   
PMH21  COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES 
Ascher-Svanum H1, Furiak NM2, Klein RW2, Montgomery W3, Smolen LJ2, Lawson AH1, Conley RR4
1Eli Lilly and Company, Indianapolis, IN, USA, 2Medical Decision Modeling, Inc, Indianapolis, IN, USA, 3Eli Lilly Australia Pty Ltd, West Ryde, Australia, 4Lilly USA, LLC, Indianapolis, IN, USA 
   
PMH22  ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDER IN SWEDEN 
Clapham E1, Berg J2, Ekman M2, Jonsson L2
1i3 Innovus, Stockholm, Stockholm, Sweden, 2i3 Innovus, Stockholm, Sweden 
   
PMH23  PREGABALIN FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDERS (GAD) -- A COST-EFFECTIVENESS CASE STUDY OF MEXICO 
Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2, Dorantes-Aguilar J1, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico 
   
PMH24  PHARMACOECONOMIC EVALUATION OF PHARMACOLOGICAL INTERVENTIONS IN GENERALIZED ANXIETY DISORDERS (GAD) IN MEXICO 
Mould-Quevedo J1, Contreras-Hernandez I2, Davila-Loaiza G1
1Pfizer Mexico, Mexico City, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico 
   
PMH25  COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS VENLAFAXINE IN SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN SWEDEN 
Despiégel N1, Danchenko N1, Maman K2
1Lundbeck SAS, Paris, France, 2Altipharm SARL, Paris, France 
   
PMH26  THE COST BURDEN OF TREATMENT RESISTANCE IN PATIENTS WITH DEPRESSION 
Gibson TB1, Jing Y2, Carls GS1, Kim E2, Bagalman JE3, Burton WN4, Tran QV5, Pikalov A5, Goetzel RZ6
1Thomson Reuters, Ann Arbor, MI, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Thomson Reuters, WASHINGTON, DC, USA, 4University of Illinois, Chicago, IL, USA, 5Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 6Emory University/Thomson Reuters, Washington, DC, USA 
   
PMH27  INPATIENT COST OF SCHIZOPHRENIA TREATMENT IN TURKEY 
Ayer A1, Sariöz F2, Kanbur B2, Yapici A1, Mizrak Demet S1, Tatar F2
1Manisa Mental Diseases Training and Research Hospital, Manisa, Turkey, 2Janssen-Cilag, Istanbul, Istanbul, Turkey 
   
PMH28  DIRECT COSTS OF PATIENTS WITH TREATMENT RESISTANT AND NON-TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER 
Ivanova J1, Birnbaum HG2, Kidolezi Y2, Subramanian G1, Stensland MD3, Khan SA3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA 
   
PMH29  DIRECT COSTS IN OLDER PATIENTS WITH DEPRESSION TREATED AND UNTREATED WITH ANTIDEPRESSANT THERAPY 
Ivanova JI1, Birnbaum HG2, Samuels S1, Emani S3, Sheehy M4, Cattelin F5
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3MGH Institute of Health Professions, Boston, MA, USA, 4Fallon Clinic, Inc, Worcester, MA, USA, 5sanofi-aventis R&D, Paris, France 
   
PMH30  HOSPITALIZATION COSTS FOR SCHIZOPHRENIA RELAPSES IN A PUBLIC PSYCHIATRIC INSTITUTION 
Verduzco W1, Escobedo O2, Anaya P3
1Mexican Social Security Institute, Mexico City, Mexico, 2Mexican Social Security Institute, Mexico City, D.F, Mexico, 3AstraZeneca, Naucalpan, Edo. de Méx, Mexico 
   
PMH31  ASSOCIATION BETWEEN CHOICE OF ANTIPSYCHOTIC TREATMENT AND SUBSEQUENT COSTS OF MEDICAL CARE IN PATIENTS WITH BIPOLAR DISORDER 
Mychaskiw MA1, Sanders KN1, Alvir J1, Montejano LB2, Lenhart G3, O'Gorman C1
1Pfizer, New York, NY, USA, 2Thomson Reuters, Washington, DC, USA, 3Thomson Reuters, Cambridge, MA, USA 
   
PMH32  ANTIPSYCHOTIC TREATMENT CHOICE AND ASSOCIATED COSTS OF MEDICAL CARE IN PATIENTS WITH SCHIZOPHRENIA 
Sanders KN1, Mychaskiw MA1, Alvir J1, Lenhart G2, Palmer L3, O'Gorman C1
1Pfizer, New York, NY, USA, 2Thomson Medstat, Cambridge, MA, USA, 3Thomson Reuters, Ann Arbor, MI, USA 
   
PMH33  ECONOMIC IMPLICATION OF DOSE ESCALATION IN DEPRESSED PATIENTS TREATED WITH ESCITALOPRAM OR VENLAFAXINE XR 
Yu AP1, Bensimon AG1, Wu EQ1, Ben-Hamadi R1, Bourezak A1, Erder MH2
1Analysis Group, Inc., Boston, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA 
   
PMH34  TREATMENT BURDEN AND COSTS OF LISDEXAMFETAMINE DIMESYLATE USERS COMPARED WITH USERS OF OTHER LONG-ACTING TREATMENTS IN PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER 
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden Prairie, MN, USA 
   
PMH35  NATIONAL ESTIMATES OF HEALTH SERVICE USE AND COSTS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN 2004-5 
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA 
   
PMH36  COMPARISON OF HOSPITALIZATIONS AND HEALTH CARE COSTS OF ELDERLY MAJOR DEPRESSIVE DISORDER (MDD) PATIENTS TREATED WITH ESCITALOPRAM, GENERIC SSRIS, OR SNRIS 
Wu EQ1, Cahill KE1, Bieri C1, Ben-Hamadi R1, Yu AP1, Erder MH2
1Analysis Group, Inc., Boston, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA 
   
PMH37  WITHDRAWN
   
PMH38  THE ECONOMIC IMPACT OF GENERIC SWITCHING FOR PATIENTS WITH MAJOR DESPRESSIVE DISORDER (MDD) TREATED WITH ESCITALOPRAM OR A PATENTED SSRI 
Lauzon V1, Kaltenboek A2, Yu AP2, Ramakrishnan K2, Marynchenko M1, Wu EQ2, Ben-Hamadi R2, Erder MH3, Bose A3
1Analysis Group, Inc., Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Forest Research Institute, Jersey City, NJ, USA 
MENTAL HEALTH Patient-Reported Outcomes Studies
PMH39  WITHDRAWN
 
 
   
PMH40  UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE IN A GERIATRIC POPULATION: DRUG-DRUG INTERACTIONS AND THEIR IMPLICATIONS FOR ADHERENCE 
Mark TL1, Joish VN2, Hay JW3, Sheehan D4, Choi JC5, Johnston S1, Cao Z6
1Thomson Healthcare, Inc, Washington, DC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3University of Southern California, Los Angeles, CA, USA, 4University of South Florida College of Medicine, Tampa, FL, USA, 5Rutgers University, Piscataway, NJ, USA, 6Thomson Healthcare, Inc, Cambridge, MA, USA 
Gibson TB1, Chen CC2, Kim E2, Jing Y2, Chu BC3, Wang SS4, Bagalman JE5, Tran QV6, Whitehead R6
   
PMH41  ADHERENCE AND PERSISTENCE TO SECOND-GENERATION ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN PATIENTS ENROLLED IN EMPLOYER-SPONSORED HEALTH PLANS 
Gibson TB1, Chen CC2, Kim E2, Jing Y2, Chu BC3, Wang SS4, Bagalman JE5, Tran QV6, Whitehead R6
1Thomson Reuters, Ann Arbor, MI, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Thomson Reuters, Santa Barbara, CA, USA, 4Thomson Reuters, Cambridge, MA, USA, 5Thomson Reuters, WASHINGTON, DC, USA, 6Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH42  IMPACT OF ALTERNATIVE DEFINITIONS OF MEDICATION COMPLIANCE ON FIRST YEAR TREATMENT COST FOR PATIENTS WITH SCHIZOPHRENIA 
Zolfaghari S1, McCombs JS2
1MedImpact Healthcare Systems, Inc., San Diego, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
Kim E1, Gupta S2, Bogle SC2, Chen CC1, Whitehead R3, Bates JA1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Consumer Health Sciences, Princeton, NJ, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH43  UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE IN A GERIATRIC POPULATION: THE BURDEN OF SIDE-EFFECTS ON ADHERENCE AND COSTS 
Mark TL1, Joish VN2, Hay JW3, Sheehan D4, Choi JC5, Johnston S1, Cao Z6
1Thomson Healthcare, Inc, Washington, DC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3University of Southern California, Los Angeles, CA, USA, 4University of South Florida College of Medicine, Tampa, FL, USA, 5Rutgers University, Piscataway, NJ, USA, 6Thomson Healthcare, Inc, Cambridge, MA, USA 
   
PMH44  IMPACT OF REJECTED CLAIMS ON PERSISTENCE TO SECOND GENERATION ANTI-PSYCHOTIC MEDICATIONS 
Zeng F1, Patel BV1, Kim E2, Knoth RL2, Chen CC2, Tran QV3, Pikalov A3
1MedImpact Healthcare Systems, Inc., San Diego, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH45  THE ASSOCIATION OF COPAY BURDEN AND MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA 
Kim E1, Gupta S2, Bogle SC2, Chen CC1, Whitehead R3, Bates JA1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Consumer Health Sciences, Princeton, NJ, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH46  PREDICTORS OF DULOXETINE TREATMENT PERSISTENCE FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER 
Gelwicks SC1, Faries DE1, Ye W1, Liu X2
1Lilly USA, LLC, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA 
   
PMH47  REASONS FOR DISCONTINUATION AND CONTINUATION OF ANTIPSYCHOTIC THERAPY FROM PATIENT AND CLINICIAN PERSPECTIVES 
Nyhuis AW1, Ascher-Svanum H2, Stauffer V1, Kinon BJ2, Faries DE1, Phillips GA2, Perkins D3
1Lilly USA, LLC, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3University of North Carolina School of Medicine, Chapel Hill, NC, USA 
   
PMH48  BURDEN OF ILLNESS OF DEPRESSION SYMPTOMS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS 
Bolge SC, Samuel W
Consumer Health Sciences International, Princeton, NJ, USA 
   
PMH49  ASSESSMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SYMPTOMS OF ADHD: PATIENT CHARACTERISTICS AND RESOURCE UTILIZATION DATA FROM AN INTERNET-BASED SURVEY 
Khan SA1, Zagar AJ2, Hayes CP1, DiBenedetti DB3, Zhou X3, Price M3, Van Brunt DL1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA 
   
PMH50  THE VALIDATION OF TURKISH VERSION OF PERSONAL AND SOCIAL PERFORMANCE SCALE (PSP) 
Aydemir O1, Ucok A2, Danaci AE1, Sariöz F3, Canpolat T3, Karadayi G2, Emiroglu B2
1Celal Bayar University, School of Medicine, Manisa, Turkey, 2Istanbul University, School of Medicine of Istanbul, Istanbul, Turkey, 3Janssen-Cilag, Istanbul, Istanbul, Turkey 
   
PMH51  PSYCHOMETRIC PROPERTIES OF THE LIFE PARTICIPATION SCALE FOR ADULTS ASSESSING DEFICITS IN ADAPTIVE FUNCTIONING 
Saylor KE1, Sutton V2, Khan SA3
1Neuroscience, Inc, Herndon, VA, USA, 2i3 Research, Cary, NC, USA, 3Eli Lilly and Company, Indianapolis, IN, USA 
   
PMH52  EVALUATING CENTRAL NERVOUS SYSTEM DRUG LABELS FOR PATIENT-REPORTED OUTCOMES CLAIMS 
Viswanathan S, Gemmen EK, Bharmal M
Quintiles, Inc, Falls Church, VA, USA 
   
PMH53  THE ASSOCIATION OF COPAY BURDEN AND OUTCOMES AMONG PATIENTS WITH SCHIZOPHRENIA 
Kim E1, Gupta S2, Bogle SC2, Chen CC1, Whitehead R3, Bates JA1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Consumer Health Sciences, Princeton, NJ, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH54  PATIENT-REPORTED HEALTH STATUS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 2004-2005 
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA 
   
PMH55  DIFFICULT TO SWALLOW: PATIENT PREFERENCES REGARDING ALTERNATIVE VALPROATE PHARMACEUTICAL FORMULATIONS 
Bhosle MJ1, Benner JS1, DeKoven M1, Shelton J2
1IMS Health, Falls Church, VA, USA, 2Answers & Insights Market Research, Inc, Indianapolis, IN, USA 
   
PMH56  MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE ER AFTER SUBOPTIMAL RESPONSE TO ORAL RISPERIDONE 
Canuso CM1, Grinspan A1, Merriman UE1, Damaraju C1, Dirani RG1, Kalali A2, Alphs L1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Quintiles, Inc, San Diego, CA, USA 
   
PMH57 JOB SATISFACTION AMONG HOSPITAL PHARMACISTS IN TAIWAN
Lee CF1, Liou WS2, Hsieh SC3
1Tri-Service General Hospital, Taipei, Taiwan, 2Medical Affair Bureau, MND, Taipei, Taiwan, 3National Taiwan University, College of Public Health, Taipei City, Taiwan
MENTAL HEALTH Health Care Use & Policy Studies
PMH58  OUTCOMES ASSESSMENT OF AN ANTIPSYCHOTIC DRUG ALGORITHM: EFFECTS OF THE MISSISSIPPI STATE HOSPITAL ALGORITHM PROJECT 
Crabtree BL1, Dostrow VG1, Evans CJ1, Cuffel BJ2, Dodge WE2, Sanders KN2
1Mississippi State Hospital, Whitfield, MS, USA, 2Pfizer, New York, NY, USA 
   
PMH59  THE IMPACT OF THE FDA ANTIDEPRESSANT BLACK BOX WARNING ON THE CONTINUITY OF ANTIDEPRESSANT TREATMENT IN CHILDREN WITH DEPRESSION 
Pawar DS, Saundankar V, Akinwunmi P, Tseng F, Chen H
University of Houston, Houston, TX, USA 
   
PMH60  EFFECT OF BLACK-BOX WARNING ON TIME TO SWITCH FROM ANTIDEPRESSANTS TO ANTIPSYCHOTICS AMONG CHILDREN SUFFERING FROM DEPRESSIVE DISORDERS IN TEXAS 
Bhowmik D1, Dwibedi N2, Goyal R1, Chen H1
1University of Houston, Houston, TX, USA, 2University of Houston, HOUSTON, TX, USA 
   
PMH61  THE EFFECTS OF ANTIDEPRESSANT STEP-THERAPY PROTOCOLS ON PHARMACEUTICAL AND MEDICAL UTILIZATION AND EXPENDITURES 
Mark TL1, Gibson TB2, Chu BC3, McGuigan K4
1Thomson Reuters, Washington, DC, USA, 2Thomson Healthcare, Inc, Ann Arbor, MI, USA, 3Thomson Healthcare, Inc, Santa Barbara, CA, USA, 4Pfizer Global Pharmaceuticals, New York, NY, USA 
   
PMH62  PREDICTORS OF OUTPATIENTS VISITS AND EMERGENCY ROOM VISITS IN PATIENTS WITH EARLY PSYCHOTIC ILLNESS 
Kolasa K1, Sweitzer DE2
1AstraZeneca, Södertälje, Sweden, 2AstraZeneca, Wilmington, DE, USA 
   
PMH63  EFFECTS OF FISCAL INCENTIVES AND SOCIOECONOMIC FACTORS ON ANTIDEPRESSANT ADHERENCE 
Able S1, Engel-Nitz NM2, Fang Y2, Ball D1
1Eli Lilly and Company, Indianapolis, IN, USA, 2i3 Innovus, Eden Prairie, MN, USA 
   
PMH64  MEASUREMENTS OF ADHERENCE TO ANTI-DEPRESSANT MEDICATIONS 
Able S1, Gelwicks SC2, Ye W2, Watson PR1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA 
   
PMH65  EFFECT OF HEALTH INSURANCE COVERAGE AND DEPRESSION ON PRESCRIPTION MEDICATION USE IN PATIENTS WITH CHRONIC MEDICAL DISORDERS 
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA 
   
PMH66  ANTIDEPRESSANTS AND ANTIPSYCHOTICS USE IN CHILDREN-HAS THE UTILIZATION CHANGED AFTER SAFETY WARNINGS? 
Mehta S, Nagar SP, Aparasu R
University of Houston, Houston, TX, USA 
   
PMH67  ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL ANTIPSYCHOTICS 
Ascher-Svanum H1, Peng X2, Montgomery W3, Faries DE2, Lawson AH1, Witte M2, Novick D4, Jemiai N5, Perrin E6
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA, 3Eli Lilly Australia Pty Ltd, West Ryde, Australia, 4Eli Lilly and Company, Windlesham, Surrey, UK, 5Eli Lilly and Company, Erl Wood ELCL, UK, 6Eli Lilly and Company, Suresnes, France 
   
PMH68  IMPACT OF FAMILY STRUCTURE ON STIMULANT USE AMONG CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER 
Rabbani A, Alexander GC
University of Chicago, Chicago, IL, USA 
   
PMH70  PHYSICIANS' ATTITUDE TO PRESCRIBING ANTIDEPRESSANT THERAPY IN OLDER PATIENTS WITH DEPRESSION 
Ivanova JI1, Birnbaum HG2, Connolly C2, Emani S3, Sheehy M4, Bienfait-Beuzon C5
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3MGH Institute of Health Professions, Boston, MA, USA, 4Fallon Clinic, Inc, Worcester, MA, USA, 5sanofi-aventis R&D, Paris, France 
   
PMH71  OFF-LABEL PRESCRIPTION RATE OF ANTIDEPRESSANTS AMONG OFFICE BASED PHYSICIAN AND HOSPITAL OUTPATIENT PRACTICES DURING 2003-2005 
Panchal JM, Dhing CW
St. John's University, Queens, NY, USA 
   
PMH72  IMPACT OF PHARMACY BENEFIT DESIGN ON ANTI-PSYCHOTIC MEDICATION ADHERENCE AND DISCONTINUATION 
Knoth RL1, Chen CC1, Kim E1, Zeng F2, Patel BV2, Leslie S2, Tran QV3, Pikalov A3
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2MedImpact Healthcare Systems, Inc., San Diego, CA, USA, 3Otsuka America Pharmaceutical, Inc, Rockville, MD, USA 
   
PMH73  DISCREPANCIES BETWEEN KNOWLEDGE, ATTITUDES AND BELIEFS AND THE ACTUAL PRACTICE (KABP) OF PHYSICIANS WHO CARE FOR PATIENTS WITH DEPRESSION AND/OR BIPOLAR DISORDER 
Jewell M1, Keck P2, Golden WE3, Brewster C1, Farley AP1
1EPI-Q, Inc., Oak Brook, IL, USA, 2University of Cincinnati, Cincinnati, OH, USA, 3University of Arkansas for Medical Sciences, Little Rock, AR, USA 
   
PMH74  COMORBID ANXIETY AND HEALTH CARE UTILIZATION AMONG ADULTS WITH DEPRESSION 
Wu CH, Erickson S
University of Michigan, Ann Arbor, MI, USA 
   
PMH75  AUTISM-RELATED HOSPITALIZATIONS: ESTIMATES FROM 2006 HEALTH CARE COST AND UTILIZATION PROJECT KIDS' INPATIENT DATABASE 
Khanna R, Madhavan SS
West Virginia University, Morgantown, WV, USA 
   
PMH76  PREDICTORS OF HIGHER HEALTH CARE EXPENDITURES IN PATIENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER 
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden Prairie, MN, USA 
   
PMH77  IMPACT OF THE BRAZILIAN PUBLIC MENTAL HEALTH POLICY ON SCHIZOPHRENIA HOSPITALIZATION: A 10-YEAR ANALYSIS 
Araujo GT, Fonseca MCM
UNIFESP -- Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil 
   
PMH78  HOSPITALIZATION RATES AMONG INDIVIDUALS WITH BIPOLAR DISORDER INITIATING THERAPY WITH ARIPIPRAZOLE OR QUETIAPINE 
Hassan M1, Lage MJ2
1AstraZeneca, Wilmington, DE, USA, 2HealthMetrics Outcomes Research, LLC, Groton, CT, USA 
   
PMH79  IDENTIFICATION OF TREATMENT RESISTANT DEPRESSION IN CLAIMS DATA: A COMPARISON OF METHODS 
Gibson TB1, Jing Y2, Bagalman JE3, Kim E2, Burton WN4, Carls GS5, Tran QV6, Pikalov A6, Goetzel RZ7
1Thomson Healthcare, Inc, Ann Arbor, MI, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Thomson Reuters, WASHINGTON, DC, USA, 4University of Illinois, Chicago, IL, USA, 5Thomson Reuters, Ann Arbor, MI, USA, 6Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 7Emory University/Thomson Reuters, Washington, DC, USA 
   
PMH80  WITHDRAWN
 
 
   
PMH81  THE IMPACT OF SUBTHERAPEUTIC INITIAL DOSING ON ADHERENCE TO ANTI-DEPRESSANTS IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY 
Able S1, Bledsoe S1, Gelwicks SC2, Watson PR1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA 
   
PMH82  PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN ADULTS 
Xiao X1, Damaraju C2, Durkin M2
1XYX Consulting Service Inc, Paoli, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA 
   
PMH83  FACTORS THAT INFLUENCE DECISIONS AMONG MBHO NETWORK PHYSICIANS TO USE OFFICE-BASED OPIOID TREATMENT OR TO INCREASE THE NUMBER OF OPIOID-DEPENDENT PATIENTS THEY TREAT: RESULTS FROM THE OBOT ATTITUDE AND INTENTION PHYSICIAN SURVEY 
Ruetsch C, Schoenberger C
Health Analytics, LLC, Columbia, MD, USA 
   
PMH84  AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID BENEFICIARIES 
Esposito D1, Verdier JM2
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Mathematica Policy Research, Inc, Washington, DC, USA 
   
PMH85  PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN CHILDREN AND ADOLESCENTS 
Xiao X1, Damaraju C2, Durkin M2
1XYX Consulting Service Inc, Paoli, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA 
   
PMH86  CONTINUITY OF CARE FOLLOWING HOSPITALIZATION FOR BIPOLAR DISORDER IN PRIVATE PAYER CLAIMS 
Stensland MD1, Peng X2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA 
   
PMH87  TREATMENT PATTERNS BY RACE/ETHNICITY AND INCOME LEVELS AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SUBJECTS TREATED WITH SHORT-, INTERMEDIATE-AND LONG-ACTING STIMULANTS 
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden Prairie, MN, USA 
   
PMH88  A SYSTEMATIC EVALUATION OF PUBLISHED LITERATURE TO ASSESS BURDEN OF TREATMENT-RESISTANT DEPRESSION 
Cyr P1, Bockstedt L2, Olchanski N1, Halseth M2, Partlow K3, Lindeke C2, Handke B2, Goss T3
1Boston Healthcare Associates, Inc, Boston, MA, USA, 2Medtronic Neuromodulation, Fridley, MN, USA, 3Boston Healthcare Associates, Inc, Washington, DC, USA 
POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday May 20, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS: Wednesday May 20, 2009 - 8:00AM-3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday May 20, 2009 - 9:30AM-10:30AM
DISMANTLE: Wednesday May 20, 2009 - 3:00PM-3:30PM

NEUROLOGICAL DISORDERS Clinical Outcomes Studies
PND1  PREVALENCE OF INSOMNIA IN EUROPE: A COMPARISON OF FIVE COUNTRIES 
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany 
   
PND2  CHRONIC MIGRAINE CRITERIA AND THEIR EFFECTS ON GLOBAL PREVALENCE ESTIMATES: A SYSTEMATIC REVIEW 
Natoli JL1, Manack A2, Dean BB1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Allergan, Inc., Irvine, CA, USA 
   
PND3  PREVALENCE OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA AND THE CO-EXISTING CONDITIONS IN MANAGED CARE ORGANIZATIONS 
Liu M1, Ganguly R2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA 
   
PND4  RATE OF DISEASE PROGRESSION AMONG PATIENTS WITH PARKINSON'S DISEASE IN SINGAPORE 
Zhao YJ1, Tan LC2, Seah SH2, Lau PN2, Au WL2, Li SC3, Luo N1, Wee HL1
1National University of Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore, 3University of Newcastle, Callaghan, Australia 
   
PND5  CLINICAL CONSEQUENCES OF GENERIC SWITCHES OF ANTI-EPILEPTIC DRUGS - TRANSFER OF CANADIAN CLAIMS DATABASE RESULTS TO GERMANY 
Bonthapally V1, Gaudig M2
1University of Louisiana at Monroe, Monroe, LA, USA, 2Janssen-Cilag, Neuss, Germany 
NEUROLOGICAL DISORDERS Cost Studies
PND6  COMPARISON OF COSTS FOR INTERFERON BETA 1-A AND NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS 
Kozma C1, Dickson M2, Meletiche DM3
1University of South Carolina, West Columbia, SC, USA, 2University of South Carolina, Columbia, SC, USA, 3EMD Serono, Inc, Rockland, MA, USA 
   
PND7  RELATION OF HEADACHE FREQUENCY TO HEALTH CARE UTILIZATION, WORK PRODUCTIVITY, AND TOTAL COSTS: RESULTS FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION (AMPP) STUDY 
Munakata J1, Serrano D2, Klingman D1, Hazard E1, Rupnow MF3, Tierce J1, Reed M2, Stewart WF4, Lipton RB5
1IMS Consulting, Falls Church, VA, USA, 2Vedanta Research, Chapel Hill, NC, USA, 3Ethicon, Inc, Somerville, NJ, USA, 4Geisinger Health System, Danville, PA, USA, 5Albert Einstein College of Medicine, Bronx, NY, USA 
   
PND8  THE IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF G4 EUROPEAN COUNTRIES 
Paradis PE1, Latremouille-Viau D1, Lafeuille MH1, Lefebvre P1, Gaudig M2, Duh M3
1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Janssen-Cilag, Neuss, Germany, 3Analysis Group, Inc., Boston, MA, USA 
   
PND9  IS GENETIC TESTING IN COMBINATION WITH PREVENTIVE DONEPEZIL (ARICEPT®) TREATMENT FOR PATIENTS WITH MILD COGNITIVE IMPAIRMENT COST- EFFECTIVE? 
Djalalov S1, Yong JHE2, Saposnik G3, Hoch J4
1St. Michael's Hospital, Toronto, ON, Canada, 2St. Michael's Hospital, University of Toronto, Toronto, ON, Canada, 3St. Michael's Hospital, Toronto, ON, Canada, ON, Canada, 4University of Toronto, Toronto, ON, Canada 
   
PND10  COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM 
Getsios D1, Blume S2, Ishak KJ3, MacLaine G4
1United BioSource Corporation, Concord, MA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3United BioSource Corporation, Montreal, QC, Canada, 4Eisai Europe Limited, Hatfield, Herthfordshire, UK 
   
PND11  COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF ALZHEIMER'S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM 
Getsios D1, Blume S2, Ishak KJ3, MacLaine G4
1United BioSource Corporation, Concord, MA, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3United BioSource Corporation, Montreal, QC, Canada, 4Eisai Europe Limited, Hatfield, Herthfordshire, UK 
   
PND12  COST-EFFECTIVENESS OF RASAGILINE VERSUS ROPINIROLE EXTENDED RELEASE IN DELAYING LEVODOPA IN THE TREATMENT OF EARLY PARKINSON'S DISEASE IN THE UNITED STATES 
Farkouh R1, Wilson MR1, Tarrants ML2, Castelli-Haley J2, Armand C3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Teva Neuroscience, Kansas City, MO, USA, 3H. Lundbeck A/S, Paris, France 
   
PND13  A COST-CONSEQUENCES ANALYSIS OF THE IMPACT OF A-RATED ANTI-EPILEPTIC DRUG SWITCHING: THE MANAGED CARE PLAN PERSPECTIVE 
Hansen RN, Campbell JD, Sullivan SD
University of Washington, Seattle, WA, USA 
   
PND14  COST OF PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS PATIENTS IN THE UNITED KINGDOM 
Smalarz A1, Harrow B1, Pashos CL2, Schoeman O3
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Abt Associates, Inc., Lexington, MA, USA, 3Quintiles Consulting, Hoofddorp, Netherlands 
   
PND15  LITERATURE REVIEW ON THE GLOBAL COST OF MULTIPLE SCLEROSIS 
Birt JA1, Duhig AM1, Naci H2, Fleurence RL3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3United BioSource Corporation Health Analytics Group, Bethesda, MD, USA 
   
PND16  ECONOMIC IMPACT OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS PATIENTS IN A MANAGED CARE SETTING 
Stephenson JJ1, Kamat S1, Cai C1, Rajagopalan K2, Agarwal S3
1HealthCore, Inc., Wilmington, DE, USA, 2Biogen Idec Pharmaceuticals, Cambridge, MA, USA, 3Biogen Idec Pharmaceuticals, Wellesley, MA, USA 
   
PND17  DIRECT MEDICAL COSTS AND THE LIKELIHOOD OF HEALTH SERVICE UTILIZATION BEFORE AND AFTER INITIATION OF INTERFERON β1A-IM TREATMENT AMONG PERSONS WITH MULTIPLE SCLEROSIS (MS) 
Brook RA1, Rajagopalan K2, Kleinman NL3, Beren IA4
1The JeSTARx Group, Newfoundland, NJ, USA, 2Biogen Idec Pharmaceuticals, Cambridge, MA, USA, 3HCMS Group, Paso Robles, CA, USA, 4HCMS Group, Cheyenne, WY, USA 
   
PND18  A HEALTH ECONOMIC EVALUATION OF TRANSANAL COLONIC IRRIGATION IN SPINAL CORD INJURY PATIENTS 
Christensen P1, Andreasen J2, Ehlers L3
1Aarhus University Hospital, Aarhus C, Denmark, 2Coloplast A/S, Minneapolis, MN, USA, 3University of Aarhus, Aarhus N, Denmark 
   
PND19  EXPLORATORY ANALYSES AND MODELING FOR RELATIVE COSTS OF INFANTS WITH HYDROCEPHALUS 
Wilburn D
University of Louisville, Louisville, KY, USA 
NEUROLOGICAL DISORDERS Patient-Reported Outcomes Studies
PND20  COMPLIANCE AND PERSISTENCE OF ORAL CHOLINESTERASE INHIBITORS IN PATIENTS WITH ALZHEIMER'S DISEASE 
Vekeman F1, Laliberte F2, Kahler K3, Mody-Patel N3, Lefebvre P2, Duh MS4
1Groupe d'analyse, Ltee, Montréal, QC, Canada, 2Groupe d'analyse, Ltee, Montreal, QC, Canada, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Analysis Group, Inc., Boston, MA, USA 
   
PND21  FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS 
Meletiche DM1, Kozma C2, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of South Carolina, Columbia, SC, USA 
   
PND22  COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS 
Meletiche DM1, Kozma C2, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of South Carolina, Columbia, SC, USA 
   
PND23  PREVALENCE OF TREATMENT GAPS IN MULTIPLE SCLEROSIS PATIENTS RECEIVING DISEASE-MODIFYING DRUGS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE 
Fincher C1, Kozma C2, Meletiche DM1, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of South Carolina, Columbia, SC, USA 
   
PND24  BURDEN OF MULTIPLE SCLEROSIS ON HEALTH-RELATED QUALITY OF LIFE: BASELINE FINDINGS FROM AN OBSERVATIONAL STUDY 
Jeffery D1, Kirzinger S2, Halper J3, Preblick R4, Jia Bi Y4, Bharmal M5
1Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2University of Louisville, Louisville, KY, USA, 3MS Center at HNH, Teaneck, NJ, USA, 4Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, 5Quintiles, Inc, Falls Church, VA, USA 
   
PND25  THE IMPACT OF LENNOX-GASTAUT SYNDROME (LGS) ON HEALTH RELATED QUALITY OF LIFE - A CONCEPTUAL MODEL 
Verdian L1, Gallop K2, Wild D2, Falconer S2
1Eisai Europe Limited, Hatfield, UK, 2Oxford Outcomes Ltd, Oxford, UK 
   
PND26  UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA 
Tarride JE, Oremus M, Clayton N, Raina P
McMaster University, Hamilton, ON, Canada 
   
PND27  THE IMPACT OF DIFFERENT STAGES OF MULTIPLE SCLEROSIS ON HEALTH UTILITIES: A SYSTEMATIC REVIEW OF THE LITERATURE 
Naci H1, Fleurence R1, Birt J2, Duhig AM3
1United BioSource Corporation, Bethesda, MD, USA, 2Eli Lilly and Company, Indiana, IN, USA, 3Eli Lilly and Company, Indianapolis, IN, USA 
   
PND28  THE USE OF ELECTRONIC PATIENT-REPORTED OUTCOMES WITHIN CENTRAL NERVOUS SYSTEM PROTOCOLS 
Wenzel K1, Logsdon M1, Meacham R2, Carrick L2
1Perceptive Informatics, Waltham, MA, USA, 2Perceptive Informatics, Nottingham, UK 
   
PND29  CANADIAN PATIENT SURVEY TO ASSESS PATIENTS' PLIGHT TO MOVEMENT DISORDER DIAGNOSES AND BOTULINUM TOXIN TYPE-A (BONTA) TREATMENT - FINAL RESULTS 
Simonyi S1, Jog M2, The Canadian Movement Disorders Survey Group N3
1Allergan, Inc., Markham, ON, Canada, 2London Health Sciences Centre, London, ON, Canada, 3', ', Canada 
   
PND30  DATA ANALYSIS OF PEDIATRIC INPATIENTS DIAGNOSED WITH BRAIN ABSCESS 
Redd R
University of Louisville, Louisville, KY, USA 
   
PND31  FACTORS ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS RECEIVING NATALIZUMAB 
Agarwal S1, Stephenson JJ2, Rajagopalan K3, Kamat S2
1Biogen Idec Pharmaceuticals, Wellesley, MA, USA, 2HealthCore, Inc., Wilmington, DE, USA, 3Biogen Idec Pharmaceuticals, Cambridge, MA, USA 
   
PND32  PREDICTORS OF PATIENT- AND PHYSICIAN-REPORTED SATISFACTION/EASE-OF-USE RATINGS WITH RASAGILINE IN PARKINSON'S DISEASE 
Buck PO, Castelli-Haley J, Conner JB
Teva Neuroscience, Kansas City, MO, USA 
NEUROLOGICAL DISORDERS Health Care Use & Policy Studies
PND33  EPIDEMIOLOGIC CHARACTERISTICS AND HEALTH RESOURCE USE IN A MULTIPLE SCLEROSIS CENTER IN SAO PAULO, BRAZIL 
Sato DK, Apostolos-Pereira SL, Junqueira TF, Adoni T, Lino AM, Marchiori PE, Callegaro D
University of Sao Paulo, Sao Paulo, SP, Brazil 
   
PND34  DISEASE BURDEN AND TREATMENT PATTERNS OF PARKINSON'S DISEASE IN A LONG TERM CARE SETTING 
Narayanan S1, Tarrants ML2, Castelli-Haley J2
1TNS Healthcare, New York, NY, USA, 2Teva Neuroscience, Kansas City, MO, USA 
   
PND35  SOCIOECONOMIC FACTORS OF INSOMNIA PRESCRIPTION IN A NATIONAL DATABASE 
Lai L, Boyar J, Patel R, Lee V
Nova Southeastern University, Ft. Lauderdale, FL, USA 
   
PND36  DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH TREATMENTS OF NEUROLOGICAL DISORDERS 
Tesar T, Foltan V, Binder R
Comenius University, Bratislava, Slovak Republic 
   
PND37  ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMER'S DISEASE TREATED WITH RIVASTIGMINE VERSUS DONEPEZIL: EVIDENCE FROM HEALTH CLAIMS DATA 
Lefebvre P1, Vekeman F2, Kahler K3, Mody-Patel N3, Duh MS4, Scharre DW5
1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Groupe d'analyse, Ltee, Montréal, QC, Canada, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Analysis Group, Inc., Boston, MA, USA, 5Ohio State University, Columbus, OH, USA 
   
PND38  EMPIRICAL CLASSIFICATION OF EPILEPSY TYPES IN INSURANCE CLAIMS DATA 
Kurth T1, Lewis B2, Walker A3
1Harvard Medical School, Boston, MA, USA, 2Eisai Corporation of North America, Woodcliff Lake, NJ, USA, 3World Health Information Science Consultants, LLC, Wellesley, MA, USA 
   
PND39  ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN THE G4 EUROPEAN COUNTRIES 
Paradis PE1, Mishagina N1, Moore Y1, Lefebvre P1, Gaudig M2, Duh M3
1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Janssen-Cilag, Neuss, Germany, 3Analysis Group, Inc., Boston, MA, USA 
   
PND40  EXPLORING THE IMPACT OF DISPENSING CHANNEL ON MEDICATION ADHERENCE AMONG MULTIPLE SCLEROSIS PATIENTS
Tang J, Faris R
Accredo Health Group, Memphis, TN, USA 
   
PND41  DETECTION OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY REPORTS ASSOCIATED WITH NATALIZUMAB PRE- AND POST-RISK MINIMIZATION ACTION PLAN FROM ADVERSE EVENT REPORTING SYSTEM DATABASE 
Gandhi P1, Hartzema AG1, Spooner J2, Odia E1, Groesbeck M3, He J1
1University of Florida, Gainesville, FL, USA, 2University of the Sciences, Philadelphia, PA, USA, 3DIME, Chicago, IL, USA 
   
PND42  BRAZILIAN NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS (MS): AN EXPLORATORY STUDY ABOUT THE IMPACT OF THE PATIENT'S ADHERENCE IN THE TREATMENT COSTS 
Bueno RLP1, Godoy MR2, Suzuki C3
1UFF - Fluminense Federal University, São Paulo, Brazil, 2UFRGS - Federal University of Rio Grande do Sul, São Paulo, São Paulo - SP, Brazil, 3Novartis Biociências S/A, São Paulo, Brazil 
POSTER PRESENTATIONS SESSION III
SET-UP: Wednesday May 20, 2009 - 7:30AM-8:00AM
POSTER DISPLAY HOURS: Wednesday May 20, 2009 - 8:00AM-3:00PM
POSTER AUTHOR DISCUSSION HOUR: Wednesday May 20, 2009 - 9:30AM-10:30AM
DISMANTLE: Wednesday May 20, 2009 - 3:00PM-3:30PM

URINARY/KIDNEY DISORDERS Clinical Outcomes Studies
PUK1  CHARACTERIZATION OF IMMUNOSUPPRESSIVE MEDICATION USE IN KIDNEY TRANSPLANTATIONS IN ACADEMIC MEDICAL CENTERS 
Kapur S1, Matuszewski K2, Oinonen M1
1University HealthSystem Consortium, Oakbrook, IL, USA, 2University HealthSystem Consortium, Oak Brook, IL, USA 
   
PUK2  RESTRICTED ACCESS TO DRUGS IS ASSOCIATED WITH LESS OPTIMAL MINERAL METABOLISM CONTROL IN HEMODIALYSIS PATIENTS 
Mendelssohn D1, Lebner A2, Soroka S3, Cournoyer S4, Da Roza G5, Geary D6, Beard K7, Folia C7, Ferreira L8
1Humber River Regional Hospital, Toronto, ON, Canada, 2University of Western Ontario, London, ON, Canada, 3QEII Health Science Centre, Halifax, NS, Canada, 4Hôpital Charles LeMoyne, Greenfield Park, QC, Canada, 5Fraser Health, New Westminster, BC, Canada, 6Hospital for Sick Children, Toronto, ON, Canada, 7Agro Health Associates, Burlington, ON, Canada, 8Genzyme Canada Inc, Mississauga, ON, Canada 
   
PUK3  CALCIUM-BASED PHOSPHATE BINDERS LEAD TO INCREASED PROGRESSION OF VASCULAR CALCIFICATION IN CHRONIC KIDNEY DISEASE 
Beard K1, Folia C1, Ferreira L2
1Agro Health Associates, Burlington, ON, Canada, 2Genzyme Canada Inc, Mississauga, ON, Canada 
   
PUK4  THE EFFECTS OF CALCIUM-BASED VS. NON CALCIUM-BASED PHOSPHATE BINDERS ON OUTCOMES AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE: A META-ANALYSIS 
Tsuyuki R1, Beard K2, Fitchett D3, Jamal S4, Lok C5, Mendelssohn D6
1University of Alberta, Edmonton, AB, Canada, 2Agro Health Associates, Burlington, ON, Canada, 3St. Michael's Hospital, University of Toronto, Toronto, ON, Canada, 4Women's College Hospital, University of Toronto, Toronto, ON, Canada, 5University Health Network, Toronto, ON, Canada, 6Humber River Regional Hospital, Toronto, ON, Canada 
   
PUK5  COMPARISON OF LIFE EXPECTANCY, EXPECTED YEARS OF LIFE LOST AND SURVIVAL BETWEEN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS 
Kao TW1, Huang JW2, Hung KY2, Chang YY1, Chen PC1, Yen CJ2, Chen YM2, Chu TS2, Wu MS2, Tsai TJ2, Wu KD2, Wang JD1
1National Taiwan University, College of Public Health, Taipei, Taiwan, 2National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan 
   
PUK6  ASSESSMENT OF CARDIOVASCULAR (CV) COMORBIDITY IN PATIENTS WITH OVERACTIVE BLADDER (OAB) DISORDER IN A REAL-WORLD SETTING 
Kim J1, Asche CV1, Kahler K2, Kulkarni AS2
1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 
URINARY/KIDNEY DISORDERS Cost Studies
PUK7  HOSPITAL DISCHARGE COST AND LENGTH OF STAY OF PERITONEAL DIALYSIS AND HEMODIALYSIS 
Walker DR1, Inglese GW2, Just PM1
1Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA, 2Baxter Healthcare Corporation, McGaw Park, IL, USA 
   
PUK8  THE COST-EFFECTIVENESS OF PARICALCITOL VERSUS STANDARD TREATMENT FOR SECONDARY HYPERPARATHYROIDISM -- MULTI-COUNTRY PERSPECTIVES 
Nuijten M1, Marx SE2, Sterz R3
1Ars Accessus Medica, Jisp, Netherlands, 2Abbott Laboratories, Abbott Park, IL, USA, 3Abbott GmbH & Co., Ludwigshafen, Germany 
   
PUK9  COST-EFFECTIVENESS ANALYSIS OF ALPHA-BLOCKER AND ANTI-MUSCARINIC COMBINATION TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS RELATED TO BENIGN PROSTATIC HYPERPLASIA AND OVERACTIVE BLADDER: APPLICATION TO THE UNITED KINGDOM 
Verheggen BG1, Lee R2, Treur MJ3, Heeg B1, Botteman M4, Mollon P5, Trocio JN6, Bavendam T6, Kaplan S2
1PharMerit Europe, Rotterdam, Netherlands, 2Weill Cornell Medical College, New York, NY, USA, 3PharMerit Europe, Rotterdam, Zuid-Holland, Netherlands, 4PharMerit North America LLC, Bethesda, MD, USA, 5Pfizer, Sandwich, Kent, UK, 6Pfizer, New York, NY, USA 
   
PUK10  LONG-TERM COST EFFECTIVENESS OF SIROLIMUS REGIMEN COMPARED WITH CALCINEURIN INHIBITOR REGIMENS FOR IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION IN KOREA 
Song HJ, Park SY, Kang SH, Bae JY, Lee EK
Sook Myung Women's University, Seoul, South Korea 
   
PUK11  WITHDRAWN
   
PUK12  CLINICAL AND ECONOMIC EVALUATION OF OVERACTIVE BLADDER PATIENTS (OAB) FAILLING TO CONSERVATIVE MANAGEMENT IN SPAIN: A FOUR HOSPITAL BASED ECONOMIC MODEL 
Arlandis S1, Castro D2, Errando C3, Fernandez E4, Jiménez M5, González P6, Crespo C7, Stauble F8, Rodriguez JM6, Brosa M9
1Hospital Universitario La Fe, Valencia, Spain, 2Hospital Clínico Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain, 3Fundació Puigvert, Barcelona, Spain, 4Hospital Ramón y Cajal, Madrid, Spain, 5Hospital Ramón y Cajal, MADRID, Spain, 6Medtronic Iberia, Madrid, Spain, 7Barcelona University, Barcelona, Spain, 8Medtronic International Trading Sarl, Tolochenaz, Switzerland, 9Oblikue Consulting, Barcelona, Spain 
   
PUK13  COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC KIDNEY DISEASE 
Rosselli D1, DeAntonio R2, Calderon C3, Sanabria M4
1Independiente, Bogotá, DC, Colombia, 2Independent, Bogota, Colombia, 3Independiente, Bogota, Colombia, 4Baxter Colombia, Bogota, Cundinamarca, Colombia 
   
PUK14  WITHDRAWN
 
 
URINARY/KIDNEY DISORDERS Patient-Reported Outcomes Studies
   
PUK15  QUALITY OF LIFE IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF OXYBUTYNIN CHLORIDE TOPICAL GEL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER 
Newman DK1, Sand PK2, Caramelli KE3, Thomas H3, Hoel G4
1Division of Urology, University of Pennsylvania, Philadelphia, PA, USA, 2Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine, Evanston, IL, USA, 3Watson Laboratories, Inc, Salt Lake City, UT, USA, 4Watson Pharmaceuticals, Inc, Salt Lake City, UT, USA 
   
PUK16  THE BRAZILIAN PORTUGUESE VALIDATION OF THE URINARY INCONTINENCE-SPECIFIC QUALITY OF LIFE INSTRUMENT- I-QOL 
Souza CC1, Fonseca ESM2, Fonseca MCM2, Sartori MGF2, Girão MJBC2, Castro RA2
1Federal University of São Paulo, São Paulo, Brazil, 2UNIFESP --University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil 
   
PUK17  THE FDA DRAFT GUIDANCE ON PATIENT-REPORTED OUTCOMES CAN BE USED TO IMPROVE THE ESTIMATION OF UTILITIES. A CASE STUDY IN CHRONIC KIDNEY DISEASE 
Lloyd A1, Falconer S1, Halton J2, Pandya B3, Pang F2
1Oxford Outcomes Ltd, Oxford, UK, 2Takeda Global Research and Development (Europe), London, UK, 3Takeda Pharmaceuticals North America, Inc, Deerfield, IL, USA 
   
PUK18  PATIENT PREFERENCE FOR TAMSULOSIN OCAS (ORAL CONTROLLED ABSORPTION SYSTEM) OVER TAMSULOSIN MODIFIED RELEASE CAPSULES 
Khastgir J1, Odeyemi I2, Sidhu M2
1Morriston Hospital ABM University Hospitals Trust, Swansea, Wales, UK, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK 
   
PUK19  IMPACT OF SOLIFENACIN ON SYMPTOM BOTHER, HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, TREATMENT SATISFACTION, AND SYMPTOMS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM VIBRANT 
Mitcheson HD1, Roy JB2, Gilmet G3, Marshall TS3, Shannon JB4
1Bay State Clinical Trials, Inc, Watertown, MA, USA, 2Edmond Medical Center, Edmond, OK, USA, 3Astellas Pharma US, Inc., Deerfield, IL, USA, 4GlaxoSmithKline, Research Triangle Park, NC, USA 
URINARY/KIDNEY DISORDERS Health Care Use & Policy Studies
PUK20  PROFILING COMMON CO-MORBIDITIES AND MEDICATIONS PRESCRIBED AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE 
Rasu R1, Karve S2, Abercrombie M3, Balkrishnan R2
1University of Missouri- Kansas City, Kansas City, MO, USA, 2Ohio State University, Columbus, OH, USA, 3University of Missouri Kansas City, Kansas City, MO, USA 
   
PUK21  IMPACTS OF THE PREVENTIVE TREATMENT OF PATIENTS SUFFERING FROM RECURRING CYSTITIS BY MEANS OF A STANDARD DRY CRANBERRY EXTRACT 
Taieb C
Pierre Fabre, Boulogne, France 
14th Annual International Meeting Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.